<SEC-DOCUMENT>0000950170-22-027006.txt : 20221223
<SEC-HEADER>0000950170-22-027006.hdr.sgml : 20221223
<ACCEPTANCE-DATETIME>20221223161031
ACCESSION NUMBER:		0000950170-22-027006
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20221220
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221223
DATE AS OF CHANGE:		20221223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Terns Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001831363
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39926
		FILM NUMBER:		221485476

	BUSINESS ADDRESS:	
		STREET 1:		1065 EAST HILLSDALE BLVD., SUITE 100
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		650-525-5535 EXT.101

	MAIL ADDRESS:	
		STREET 1:		1065 EAST HILLSDALE BLVD., SUITE 100
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tern-20221220.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-12-23T11:41:23.6184+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:tern="http://www.ternspharma.com/20221220">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_70cae8a6-f93f-4355-b4c0-48ecb92d83ab" name="dei:EntityCentralIndexKey" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d">0001831363</ix:nonNumeric><ix:nonNumeric id="F_670ea391-7606-4662-8217-3bde398a9fee" name="dei:AmendmentFlag" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tern-20221220.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-20</xbrli:startDate><xbrli:endDate>2022-12-20</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="border-top:2.25pt double rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6dde87ab-255e-49f4-a80f-a2a0e639d420" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6fa2c7cb-9ebf-4771-a53f-e99bab4ade82" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 20, 2022</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e7e7d471-8020-4f02-9ca4-9983769a12d5" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:24.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Terns Pharmaceuticals, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:41.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_36c2503b-6de9-42ce-a505-59185812da68" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3e0b09e9-4aec-44d9-89db-4d2bdc55d4c1" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39926</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fba26801-fae5-406a-abf8-356380d050e4" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98-1448275</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or Other Jurisdiction<br />of Incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(IRS Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7d1433b9-525a-4ed6-8625-a830bfe198a4" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1065 East Hillsdale Blvd.</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d30cac4a-3edf-4fe6-94ca-f69d63c8b112" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suite 100</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5a889093-8885-4358-9316-750fba17331b" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foster City</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_15e1a5c9-ccf3-4854-ada7-e6cc8945844b" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_54c451eb-dc4d-4427-b454-bd55e46078b5" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94404</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s Telephone Number, Including Area Code:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0eaa1010-eef7-4889-bccc-79408da2a5e3" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_724c6679-48ce-46fb-9cac-c2b0c03a3a3b" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">525-5535</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_144144a4-72f6-4308-85e8-0ec04476a354" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:EntityInformationFormerLegalOrRegisteredName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">N/A</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2c7b914d-1c50-4a97-a461-41a5f86ea43b" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_43ac8139-8d66-492d-a3ba-57827a5f834b" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_adfd61fb-03a4-4cb9-bd78-b8dd80239d5b" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c18f266f-3d5b-4193-8d22-f9c1bb103f80" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:9.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading<br />Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4d0721e5-7d65-4091-b6e2-feab82498be7" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2d63acae-de75-4d38-819f-52db76da48e0" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TERN</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6f0de68c-9370-4269-9bf6-e81e90068a89" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NASDAQ Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x202f;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x202f;240.12b-2 of this chapter).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_7b20e325-8dd6-4c63-b919-bd9028b94189" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_cffc3da8-85fa-4c3f-acb1-1494f1520d29" contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double rgba(0,0,0,1);text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.01 Other Events.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 20, 2022, Terns Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) entered into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with Jefferies LLC and Cowen and Company, LLC, as representatives of the several underwriters named in Schedule 1 thereto (collectively, the &#x201c;Underwriters&#x201d;), relating to the underwritten public offering of 10,350,000 shares (the &#x201c;Shares&#x201d;) of the Company&#x2019;s common stock, $0.0001 par value per share (the &#x201c;Common Stock&#x201d;) at a public offering price per share of $7.25 (the &#x201c;Offering&#x201d;). Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable within 30 days from the date of the Underwriting Agreement, to purchase up to 1,552,500 additional shares of Common Stock (the &#x201c;Option Shares&#x201d;), which the Underwriters exercised in full on December 21, 2022. The closing of the Offering took place on December 23, 2022. All of the Shares were sold by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company estimates that the net proceeds from the Offering are approximately $80.8 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, and including the full exercise of the Underwriters&#x2019; option to purchase the Option Shares.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Offering was made pursuant to a shelf registration statement on Form S-3 (File No. 333-263370) (the &#x201c;Registration Statement&#x201d;) that was filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 8, 2022 and declared effective by the SEC on March 14, 2022, a prospectus included in the Registration Statement, a preliminary prospectus supplement, which was filed with the SEC on December 20, 2022, and a final prospectus supplement, which was filed with the SEC on December 21, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Underwriting Agreement contains customary representations, warranties, covenants, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act, and other obligations of the parties. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. The foregoing is only a brief description of the terms of the Underwriting Agreement, does not purport to be a complete statement of the rights and obligations of the parties under the Underwriting Agreement and the transactions contemplated thereby, and is qualified in its entirety by reference to the Underwriting Agreement, which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A copy of the legal opinion of Latham &amp; Watkins LLP relating to the validity of the issuance and sale of the Shares in the Offering is filed as Exhibit 5.1 to this Current Report on Form 8-K and is filed with reference to, and is hereby incorporated by reference into, the Registration Statement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.01 Other Events.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The full text of the press release announcing the pricing of the Offering on December 20, 2022 is attached as Exhibit 99.1 hereto and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(d) Exhibits</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.87%;"></td>
    <td style="width:0.065%;"></td>
    <td style="width:94.065%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:1pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.157%;"></td>
    <td style="width:1.042%;"></td>
    <td style="width:94.801%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="tern-ex1_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Underwriting Agreement, dated December 20, 2022, among Terns Pharmaceuticals, Inc. and Jefferies LLC and Cowen and Company, LLC, as representatives of the several underwriters named therein.</span></a></p></td>
   </tr>
   <tr style="height:13.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="tern-ex5_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opinion of Latham &amp; Watkins LLP.</span></a></p></td>
   </tr>
   <tr style="height:11.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="tern-ex5_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Latham &amp; Watkins LLP (included in Exhibit 5.1).</span></a></p></td>
   </tr>
   <tr style="height:11.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="tern-ex99_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Press Release dated December 20, 2022.</span></a></p></td>
   </tr>
   <tr style="height:21.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (embedded within the inline XBRL document).</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.0%;"></td>
    <td style="width:45.0%;"></td>
    <td style="width:4.0%;"></td>
    <td style="width:46.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TERNS PHARMACEUTICALS, INC.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 23, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Bryan Yoon</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bryan Yoon<br />Chief Operating Officer &amp; General Counsel</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tern-ex1_1.htm
<DESCRIPTION>EX-1.1
<TEXT>
<html>
 <head>
  <title>EX-1.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 1.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Execution Version</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br><br><br>Terns Pharmaceuticals, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,350,000 Shares of Common Stock, Par Value $0.0001</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Underwriting Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 20, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jefferies LLC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cowen and Company, LLC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>As Representatives of the<br>several Underwriters listed<br>in Schedule 1 hereto</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">c/o Jefferies LLC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">520 Madison Avenue</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">New York, New York 10022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">c/o Cowen and Company, LLC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">599 Lexington Avenue</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">New York, New York 10022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ladies and Gentlemen:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Terns Pharmaceuticals, Inc., a Delaware corporation (the &#x201c;Company&#x201d;), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the &#x201c;Underwriters&#x201d;), for whom you are acting as representatives (the &#x201c;Representatives&#x201d;), (i) an aggregate of 10,350,000 shares of common stock, par value $0.0001 per share, of the Company (the &#x201c;Underwritten Shares&#x201d;) and (ii) at the option of the Underwriters, up to an additional 1,552,500 shares of common stock of the Company (the &#x201c;Option Shares&#x201d;). The Underwritten Shares and the Option Shares are herein referred to as the &#x201c;Shares&#x201d;. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the &#x201c;Stock&#x201d;.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that there are no additional Underwriters listed on Schedule 1 hereto, all references to the Representatives and the Underwriters shall refer just to you, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. To the extent only one Representative is listed above, all references to the term Representatives shall mean Representative in the singular form.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company hereby confirms its agreement with the several Underwriters concerning the purchase and sale of the Shares, as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company has prepared and filed with the Securities and Exchange Commission (the &#x201c;Commission&#x201d;) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#x201c;Securities Act&#x201d;), a registration statement on Form S-3 (File No. 333-263370), including a prospectus, relating to the Shares.  Such registration statement, as amended at the time it became effective, including the information, if any, deemed pursuant to Rule 430A, 430B or 430C under the Securities Act to be part of the registration statement at the time of its effectiveness (&#x201c;Rule 430 Information&#x201d;), is referred to herein as the &#x201c;Registration Statement&#x201d;; and as used herein, the term &#x201c;Preliminary Prospectus&#x201d; means each prospectus included in such registration statement (and any amendments thereto) before effectiveness, any prospectus filed with the Commission pursuant to Rule 424(a) under the Securities Act and the prospectus included in the Registration Statement at the time of its effectiveness that omits Rule 430 Information (the &#x201c;Base Prospectus&#x201d;), and the preliminary prospectus supplement thereto dated December 20, 2022 relating to the Shares, and the term &#x201c;Prospectus&#x201d; means the Base Prospectus and prospectus supplement relating to the Shares in the form first used (or made available upon request of purchasers pursuant to Rule 173 under the Securities Act) in connection with confirmation of sales of the Shares.  If the Company has filed an abbreviated registration statement pursuant to Rule 462(b) under the Securities Act (the &#x201c;Rule 462 Registration Statement&#x201d;), then any reference herein to the term &#x201c;Registration Statement&#x201d; shall be deemed to include such Rule 462 Registration Statement. Any reference in this underwriting agreement (this &#x201c;Agreement&#x201d;) to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form S-3 under the Securities Act, as of the effective date of the Registration Statement or the date of such Preliminary Prospectus or the Prospectus, as the case may be, and any reference to &#x201c;amend&#x201d;, &#x201c;amendment&#x201d; or &#x201c;supplement&#x201d; with respect to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any documents filed after such date under the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#x201c;Exchange Act&#x201d;) that are deemed to be incorporated by reference therein. Capitalized terms used but not defined herein shall have the meanings given to such terms in the Registration Statement and the Prospectus.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At or prior to the Applicable Time (as defined below), the Company had prepared the following information (collectively with the pricing information set forth on Annex A, the &#x201c;Pricing Disclosure Package&#x201d;): a Preliminary Prospectus dated December 20, 2022 and each &#x201c;free-writing prospectus&#x201d; (as defined pursuant to Rule 405 under the Securities Act) listed on Annex A hereto.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Applicable Time&#x201d; means 5:15 P.M., New York City time, on December 20, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of the Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company agrees to issue and sell the Underwritten Shares to the several Underwriters as provided in this Agreement, and each Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase at a price per share of $6.815 (the &#x201c;Purchase Price&#x201d;) from the Company the respective number of Underwritten Shares set forth opposite such Underwriter&#x2019;s name in Schedule 1 hereto.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the Company agrees to issue and sell the Option Shares to the several Underwriters as provided in this Agreement, and the Underwriters, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, shall have the option to purchase, severally and not jointly, from the Company the Option Shares at the Purchase Price less an amount per share equal to any dividends or distributions declared by the Company and payable on the Underwritten Shares but not payable on the Option Shares.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any Option Shares are to be purchased, the number of Option Shares to be purchased by each Underwriter shall be the number of Option Shares which bears the same ratio to the aggregate number of Option Shares being purchased as the number of Underwritten Shares set forth opposite the name of such Underwriter in Schedule 1 hereto (or such number increased as set forth in Section 10 hereof) bears to the aggregate number of Underwritten Shares being purchased from the Company by the several Underwriters, subject, however, to such adjustments to eliminate any fractional Shares as the Representatives in their sole discretion shall make.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Underwriters may exercise the option to purchase Option Shares at any time in whole, or from time to time in part, on or before the thirtieth day following the date of the Prospectus, by written notice from the Representatives to the Company. Such notice shall set forth the aggregate number of Option Shares as to which the option is being exercised and the date and time when the Option Shares are to be delivered and paid for, which may be the same date and time as the Closing Date (as hereinafter defined) but shall not be earlier than the Closing Date nor later than the tenth full business day (as hereinafter defined) after the date of such notice (unless such time and date are postponed in accordance with the provisions of Section 10 hereof). Any such notice shall be given at least two business days prior to the date and time of delivery specified therein.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company understands that the Underwriters intend to make a public offering of the Shares, and initially to offer the Shares on the terms set forth in the Pricing Disclosure Package.  The Company acknowledges and agrees that the Underwriters may offer and sell Shares to or through any affiliate of an Underwriter.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payment for the Shares shall be made by wire transfer in immediately available funds to the account specified by the Company to the Representatives in the case of the Underwritten Shares at the offices of Davis Polk &amp; Wardwell LLP, 450 Lexington Avenue, New York, New York 10017 at 10:00 A.M. New York City time on </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 23, 2022, or at such other time or place on the same or such other date, not later than the fifth business day thereafter, as the Representatives and the Company may agree upon in writing or, in the case of the Option Shares, on the date and at the time and place specified by the Representatives in the written notice of the Underwriters&#x2019; election to purchase such Option Shares. The time and date of such payment for the Underwritten Shares is referred to herein as the &#x201c;Closing Date,&#x201d; and the time and date for such payment for the Option Shares, if other than the Closing Date, is herein referred to as the &#x201c;Additional Closing Date.&#x201d;</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payment for the Shares to be purchased on the Closing Date or the Additional Closing Date, as the case may be, shall be made against delivery to the Representatives for the respective accounts of the several Underwriters of the Shares to be purchased on such date or the Additional Closing Date, as the case may be, with any transfer taxes payable in connection with the sale of such Shares duly paid by the Company. Delivery of the Shares shall be made through the facilities of The Depository Trust Company (&#x201c;DTC&#x201d;) unless the Representatives shall otherwise instruct.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company acknowledges and agrees that the Representatives and the other Underwriters are acting solely in the capacity of an arm&#x2019;s length contractual counterparty to the Company with respect to the offering of Shares contemplated hereby (including in connection with determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company or any other person.  Additionally, neither the Representatives nor any other Underwriter is advising the Company or any other person as to any legal, tax, investment,  accounting or regulatory matters in any jurisdiction.  The Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and neither the Representatives nor the other Underwriters shall have any responsibility or liability to the Company with respect thereto.  Any review by the Representatives and the other Underwriters of the Company, the transactions contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Representations and Warranties of the Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company represents and warrants to each Underwriter that:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preliminary Prospectus.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  No order preventing or suspending the use of any Preliminary Prospectus has been issued by the Commission, and each Preliminary Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, complied in all material respects with the Securities Act, and no Preliminary Prospectus, at the time of filing thereof, contained any untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company in writing by such Underwriter through the Representatives expressly for use in any Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 7(b) hereof.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pricing Disclosure Package</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Pricing Disclosure Package as of the Applicable Time did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in such Pricing Disclosure Package, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 7(b) hereof.  No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package and no statement of material fact included in the Pricing Disclosure Package that is required to be included in the Prospectus has been omitted therefrom. </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Issuer Free Writing Prospectus.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other than the Registration Statement, the Preliminary Prospectus and the Prospectus, the Company (including its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not prepare, make, use, authorize, approve or refer to any &#x201c;written communication&#x201d; (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Shares (each such communication by the Company or its agents and representatives (other than a communication referred to in clause (i) below) an &#x201c;Issuer Free Writing Prospectus&#x201d;) other than (i) any document not constituting a prospectus pursuant to Section 2(a)(10)(a) of the Securities Act or Rule 134 under the Securities Act or (ii) the documents listed on Annex A hereto, each electronic road show, each electronic investor presentation and any other written communications approved in writing in advance by the Representatives.  Each such Issuer Free Writing Prospectus complies in all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433) filed in accordance with the Securities Act (to the extent required thereby) and does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package, and, when taken together with the Preliminary Prospectus accompanying, or delivered prior to delivery of, or filed prior to the first use of, such Issuer Free Writing Prospectus, did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">make the statements therein, in the light of the circumstances under which they were made, not misleading; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> that the Company makes no representation or warranty with respect to any statements or omissions made in each such Issuer Free Writing Prospectus or Preliminary Prospectus in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in such Issuer Free Writing Prospectus or Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 7(b) hereof.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Emerging Growth Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  As of the date hereof, the Company is an &#x201c;emerging growth company,&#x201d; as defined in Section 2(a) of the Securities Act (an &#x201c;Emerging Growth Company&#x201d;).  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Testing-the-Waters Materials.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company (i) has not alone engaged in any Testing-the-Waters Communications (as defined below) other than Testing-the-Waters Communications with the consent of the Representatives (x) with entities that are qualified institutional buyers (&#x201c;QIBs&#x201d;) within the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act (&#x201c;IAIs&#x201d;) and otherwise in compliance with the requirements of Section 5(d) of the Securities Act or (y) with entities that the Company reasonably believed to be QIBs or IAIs and otherwise in compliance with the requirements of Rule 163B  under the Securities Act and (ii) has not authorized anyone other than the Representatives to engage in Testing-the-Waters Communications. &#x201c;Testing-the-Waters Communication&#x201d; means any oral or written communication with potential investors undertaken in reliance on either Section 5(d) of, or Rule 163B under, the Securities Act. The Company has not distributed or approved for distribution any Written Testing-the-Waters Communications (as defined below) other than those listed on Annex B hereto. &#x201c;Written Testing-the-Waters Communication&#x201d; means any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the Securities Act.  Any individual Written Testing-the-Waters Communication does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package, complied in all material respects with the Securities Act, and when taken together with the Pricing Disclosure Package as of the Applicable Time, did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Registration Statement and Prospectus.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The Registration Statement has been declared effective by the Commission.  No order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or pursuant to Section 8A of the Securities Act </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">against the Company or related to the offering of the Shares has been initiated, or to the knowledge of the Company, threatened by the Commission; as of the applicable effective date of the Registration Statement and any post-effective amendment thereto, the Registration Statement and any such post-effective amendment complied and will comply in all material respects with the applicable requirements of the Securities Act, and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date and as of the Additional Closing Date, as the case may be, the Prospectus will comply in all material respects with the Securities Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 7(b) hereof.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(g)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Incorporated Documents.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The documents incorporated by reference in the Registration Statement, the Prospectus and the Pricing Disclosure Package, when they were filed with the Commission conformed in all material respects to the requirements of the Exchange Act, and none of such documents contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated by reference in the Registration Statement, the Prospectus or the Pricing Disclosure Package, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(h)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Statements.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The financial statements (including the related notes thereto) of the Company and its consolidated subsidiaries included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and present fairly in all material respects, the financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified; such financial statements have been prepared in conformity with generally accepted </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">accounting principles (&#x201c;GAAP&#x201d;) in the United States applied on a consistent basis throughout the periods covered thereby, except in the case of unaudited interim financial statements, which are subject to normal year-end adjustments and do not contain certain footnotes as permitted by the applicable rules of the Commission, and any supporting schedules included or incorporated by reference in the Registration Statement present fairly in all material respects, the information required to be stated therein; and the other financial information included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly in all material respects the information shown thereby.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No Material Adverse Change.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Since the date of the most recent financial statements of the Company included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i) there has not been any change in the capital stock (other than the issuance of shares of Common Stock upon exercise of stock options and warrants described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration Statement, the Pricing Disclosure Package and the Prospectus), short-term debt or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change, or any development that would reasonably be expected to result in a material adverse change, in or affecting the business, properties, management, financial position, stockholders&#x2019; equity, results of operations or prospects of the Company and its subsidiaries taken as a whole; (ii) neither the Company nor any of its subsidiaries has entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii) neither the Company nor any of its subsidiaries has sustained any loss or interference with its business that is material to the Company and its subsidiaries taken as a whole and that is either from fire, explosion, pandemic, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(j)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Organization and Good Standing.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The Company and each of its subsidiaries have been duly organized and are validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the business, properties, management, financial position, stockholders&#x2019; equity, results of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under this Agreement (a &#x201c;Material Adverse Effect&#x201d;).  The subsidiaries listed in Exhibit 21.1 to the Company&#x2019;s Annual Report on Form 10-K are the only significant subsidiaries of the Company.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(k)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Capitalization.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  All the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and non-assessable and are not subject to any pre-emptive or similar rights that have not been duly waived or satisfied; except as described in or expressly contemplated by the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no outstanding rights (including, without limitation, pre-emptive rights, that have not been duly waived or satisfied), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in all material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and all the outstanding shares of capital stock or other equity interests of each subsidiary owned, directly or indirectly, by the Company have been duly and validly authorized and issued, are fully paid and non-assessable (except as otherwise described in the Registration Statement, the Pricing Disclosure Package and the Prospectus,) and are owned directly or indirectly by the Company, free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(l)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Options.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With respect to the stock options (the &#x201c;Stock Options&#x201d;) granted pursuant to the stock-based compensation plans of the Company and its subsidiaries (the &#x201c;Company Stock Plans&#x201d;), (i) each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective (the &#x201c;Grant Date&#x201d;) by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (ii) each such grant was made in accordance with the terms of the applicable Company Stock Plan and all other applicable laws and regulatory rules or requirements, and (iii) each such grant was </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">properly accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company and disclosed in the Company&#x2019;s filings with the Commission in accordance with the Exchange Act and all other applicable laws.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(m)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Due Authorization.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The Company has full right, power and authority to execute and deliver this Agreement and to perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby has been duly and validly taken.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(n)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Underwriting Agreement. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> This Agreement has been duly authorized, executed and delivered by the Company.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(o)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The Shares.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Shares to be issued and sold by the Company hereunder have been duly authorized by the Company and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and nonassessable and will conform to the descriptions thereof in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(p)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Description of the Underwriting Agreement.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  This Agreement conforms in all material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(q)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No Violation or Default.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Neither the Company nor any of its subsidiaries is (i) in violation of its charter or by-laws or similar organizational documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any property or asset of the Company or any of its subsidiaries is subject; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (ii) and (iii) above, for any such default or violation that would not, individually or in the aggregate, have a Material Adverse Effect.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(r)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No Conflicts.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares and the consummation of the transactions contemplated by this Agreement or the Pricing Disclosure Package and the Prospectus will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">right or asset of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any property, right or asset of the Company or any of its subsidiaries is subject, (ii) result in any violation of the provisions of the charter or by-laws or similar organizational documents of the Company or any of its subsidiaries or (iii) result in the violation of any law or statute or any judgment, order, rule  or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i) and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in the aggregate, have a Material Adverse Effect.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(s)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No Consents Required.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares and the consummation of the transactions contemplated by this Agreement, except for the registration of the Shares under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as may be required by the Financial Industry Regulatory Authority, Inc. (&#x201c;FINRA&#x201d;) and under applicable state securities laws in connection with the purchase and distribution of the Shares by the Underwriters.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(t)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Legal Proceedings.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (&#x201c;Actions&#x201d;) pending to which the Company or any of its subsidiaries is or, may reasonably be expected to become a party or to which any property of the Company or any of its subsidiaries is or may be the subject that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, would reasonably be expected to have a Material Adverse Effect; to the knowledge of the Company, no such Actions are threatened or contemplated by any governmental or regulatory authority or threatened by others; and (i) there are no current or pending Actions that are required under the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and (ii) there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(u)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Independent Accountants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Ernst &amp; Young LLP, who have certified certain financial statements of the Company and its subsidiaries, is an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(v)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Title to Real and Personal Property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company and its subsidiaries have good and marketable title in fee simple (in the case of real property) to, or have valid rights to lease or otherwise use, all items of real and personal property that are material to the respective businesses of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i) do not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries or (ii) would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(w)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intellectual Property.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Except as disclosed in the Pricing Disclosure Package and the final Prospectus, (i) the Company and its subsidiaries own or have the right to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, domain names and other source indicators, copyrights and copyrightable works, know-how, trade secrets, systems, procedures, proprietary or confidential information and all other worldwide intellectual property, industrial property and proprietary rights (collectively, &#x201c;Intellectual Property&#x201d;) used, or as contemplated to be used, in the Registration Statement, in the conduct of their respective businesses; (ii) the Intellectual Property owned by the Company and its subsidiaries and, to the Company&#x2019;s knowledge, the Intellectual Property licensed to the Company and its subsidiaries, are valid, subsisting and enforceable, and there is no pending or, to the Company&#x2019;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity, scope or enforceability of any such Intellectual Property; (iii) to the knowledge of the Company, Company&#x2019;s and its subsidiaries&#x2019; conduct of their respective businesses does not infringe, misappropriate or otherwise violate, and has not infringed, misappropriated or otherwise violated, any valid Intellectual Property of any person; (iv) the Company and its subsidiaries have not received any notice of any claim challenging the Company&#x2019;s rights in or to its Intellectual Property and there are no actual or, to the knowledge of the Company, threatened claims alleging that the Company or any of its subsidiaries infringe, misappropriate or otherwise violate any third party Intellectual Property; (v) to the knowledge of the Company, the Intellectual Property of the Company and its subsidiaries is not being, and has not been, infringed, misappropriated or otherwise violated by any person; (vi) to the knowledge of the Company, all employees or contractors engaged in the development of Intellectual Property owned by the Company or its subsidiaries, on behalf of the Company or any subsidiary of the Company have executed an invention assignment agreement or </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other agreement whereby such employees or contractors assign all of their right, title and interest in and to such Intellectual Property to the Company or the applicable subsidiary, and to the Company&#x2019;s knowledge no such agreement has been breached or violated; and (vii) to the knowledge of the Company, the Company and its subsidiaries use, and have used, commercially reasonable efforts to appropriately maintain all information intended by the Company to be maintained as a trade secret</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(x)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No Undisclosed Relationships</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  No relationship, direct or indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of the Company or any of its subsidiaries, on the other, that is required by the Securities Act to be described in each of the Registration Statement and the Prospectus and that is not so described in such documents and in the Pricing Disclosure Package.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(y)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investment Company Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company is not and, after giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be required to register as an &#x201c;investment company&#x201d; or an entity &#x201c;controlled&#x201d; by an &#x201c;investment company&#x201d; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#x201c;Investment Company Act&#x201d;).</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(z)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Taxes.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The Company and its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax returns required to be paid or filed through the date hereof except where the failure to pay such taxes or file such tax returns would not, individually or in the aggregate, have a Material Adverse Effect; and except as otherwise disclosed in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no material tax deficiency that has been, or could reasonably be expected to be, asserted against the Company or any of its subsidiaries or any of their respective properties or assets.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(aa)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licenses and Permits.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The Company and its subsidiaries possess all licenses, sub-licenses, certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, except where the failure to possess or make the same would not, individually or in the aggregate, have a Material Adverse Effect; and except as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor any of its subsidiaries has received notice of any revocation or modification of any such license, sub-license, certificate, permit or authorization or has any reason to believe that any such license, sub-license, certificate, permit or authorization will </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not be renewed in the ordinary course, except for such revocations, modifications, or non-renewals, that would not, whether individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(bb)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No Labor Disputes.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  No labor disturbance by or dispute with employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its or its subsidiaries&#x2019; principal suppliers, contractors or customers, except as would not be reasonably expected to have a Material Adverse Effect.  Neither the Company nor any of its subsidiaries has received any notice of cancellation or termination with respect to any collective bargaining agreement to which it is a party.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(cc)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Certain Environmental Matters</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  (i) The Company and its subsidiaries (x) are in compliance with all, and have not violated any, applicable federal, state, local and foreign laws (including common law), rules, regulations, requirements, decisions, judgments, decrees, orders and other legally enforceable requirements relating to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#x201c;Environmental Laws&#x201d;); (y) have received and are in compliance with all, and have not violated any, permits, licenses, certificates or other authorizations or approvals required of them under any Environmental Laws to conduct their respective businesses; and (z) have not received notice of any actual or potential liability or obligation under or relating to, or any actual or potential violation of, any Environmental Laws, including for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) there are no costs or liabilities associated with Environmental Laws of or relating to the Company or its subsidiaries, except in the case of each of (i) and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii) except as described in each of the Pricing Disclosure Package and the Prospectus, (x) there is no proceeding that is pending, or that is known by the Company to be contemplated, against the Company or any of its subsidiaries under any Environmental Laws in which a governmental entity is also a party, other than such proceeding regarding which the Company reasonably believes no monetary sanctions of $100,000 or more will be imposed, (y) the Company and its subsidiaries are not aware of any facts or issues regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that would reasonably be expected to have a material effect on the capital expenditures, earnings or competitive position of the Company and its </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subsidiaries, and (z) none of the Company or its subsidiaries anticipates material capital expenditures relating to any Environmental Laws.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(dd)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Compliance with ERISA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  (i) Each employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (&#x201c;ERISA&#x201d;), for which the Company or any member of its &#x201c;Controlled Group&#x201d; (defined as any entity, whether or not incorporated, that is under common control with the Company within the meaning of Section 4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section 414(b),(c),(m) or (o) of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;) would have any liability (each, a &#x201c;Plan&#x201d;) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii) no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption; (iii) for each Plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards (within the meaning of Section 302 of ERISA or Section 412 of the Code) applicable to such Plan; (iv) no Plan is, or is reasonably expected to be, in &#x201c;at risk status&#x201d; (within the meaning of Section 303(i) of ERISA) and no Plan that is a &#x201c;multiemployer plan&#x201d; within the meaning of Section 4001(a)(3) of ERISA is in &#x201c;endangered status&#x201d; or &#x201c;critical status&#x201d; (within the meaning of Sections 304 and 305 of ERISA) (v) the fair market value of the assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no &#x201c;reportable event&#x201d; (within the meaning of Section 4043(c) of ERISA and the regulations promulgated thereunder) has occurred or is reasonably expected to occur; (vii) each Plan that is intended to be qualified under Section 401(a) of the Code is so qualified, and nothing has occurred, whether by action or by failure to act, which would cause the loss of such qualification; (viii) neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guaranty Corporation, in the ordinary course and without default) in respect of a Plan (including a &#x201c;multiemployer plan&#x201d; within the meaning of Section 4001(a)(3) of ERISA); and (ix) none of the following events has occurred or is reasonably likely to occur: (A) a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the current fiscal year of the Company and its Controlled Group affiliates compared to the amount of such contributions made in the Company&#x2019;s and its Controlled Group affiliates&#x2019; most recently completed fiscal year; or (B) a material increase in the Company and its subsidiaries&#x2019; &#x201c;accumulated post-retirement benefit obligations&#x201d; (within the meaning of Accounting Standards Codification Topic 715-60) compared to the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">amount of such obligations in the Company and its subsidiaries&#x2019; most recently completed fiscal year, except in each case with respect to the events or conditions set forth in (i) through (ix) hereof, as would not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(ee)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Disclosure Controls</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company and its subsidiaries, on a consolidated basis, maintain an effective system of &#x201c;disclosure controls and procedures&#x201d; (as defined in Rule 13a-15(e) of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#x2019;s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#x2019;s management as appropriate to allow timely decisions regarding required disclosure. The Company and its subsidiaries, on a consolidated basis, have carried out evaluations of the effectiveness of their disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(ff)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting Controls.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The Company and its subsidiaries maintain systems of &#x201c;internal control over financial reporting&#x201d; (as defined in Rule 13a-15(f) of the Exchange Act) that comply with the applicable requirements of the Exchange Act and have been designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.  The Company and its subsidiaries maintain internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management&#x2019;s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management&#x2019;s general or specific authorization; (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v) interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Prospectus and the Pricing Disclosure Package fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#x2019;s rules and guidelines applicable thereto. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no material weaknesses in the Company&#x2019;s internal controls.  The Company&#x2019;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of:  (i) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which have adversely affected or are reasonably likely to adversely affect the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company&#x2019;s ability to record, process, summarize and report financial information; and (ii) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#x2019;s internal controls over financial reporting.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(gg)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">eXtensible Business Reporting Language</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#x2019;s rules and guidelines applicable thereto.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(hh)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Insurance.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company and its subsidiaries have insurance covering their respective properties, operations, personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as the Company reasonably believes are adequate to protect the Company and its subsidiaries and their respective businesses; and neither the Company nor any of its subsidiaries has (i) received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance or (ii) any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cybersecurity; Data Protection. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(i)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Company and its subsidiaries&#x2019; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#x201c;IT Systems&#x201d;) are adequate for, and operate and perform as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants; (ii) the Company and its subsidiaries have implemented and maintained commercially reasonable controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data (including all personal, personally identifiable, sensitive, confidential or regulated data (&#x201c;Personal Data&#x201d;)) used in connection with their businesses, and there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same; and (iii) the Company and its subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unauthorized use, access, misappropriation or modification (&#x201c;Data Security Obligations&#x201d;). The Company has not received any written notification of or written complaint regarding, and is unaware of any other facts that, individually or in the aggregate, would reasonably indicate material non-compliance with any Data Security Obligation, and there is no action, suit or proceeding by or before any court or governmental agency, authority or body pending or, to the knowledge of the Company, threatened alleging non-compliance with any Data Security Obligation.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(jj)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No Unlawful Payments.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Neither the Company nor any of its subsidiaries nor any director, officer or employee of the Company or any of its subsidiaries nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office; (iii) violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law; or (iv) made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit.  The Company and its subsidiaries have instituted, maintain and enforce, and will continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(kk)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Compliance with Anti-Money Laundering Laws</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency (collectively, the &#x201c;Anti-Money Laundering Laws&#x201d;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(ll)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No Conflicts with Sanctions Laws.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Neither the Company nor any of its subsidiaries, directors, officers, or employees, nor, to the knowledge of the Company, any agent,  affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any sanctions administered or enforced by the U.S. government, (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#x201c;OFAC&#x201d;) or the U.S. Department of State and including, without limitation, the designation as a &#x201c;specially designated national&#x201d; or &#x201c;blocked person&#x201d;), the United Nations Security Council (&#x201c;UNSC&#x201d;), the European Union, His Majesty&#x2019;s Treasury (&#x201c;HMT&#x201d;) or other relevant sanctions authority (collectively, &#x201c;Sanctions&#x201d;), nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or target of Sanctions, including, without limitation, the so-called Donetsk People&#x2019;s Republic, the so-called Luhansk People&#x2019;s Republic, the Crimea region of Ukraine, Cuba, Iran, North Korea and Syria (each, a &#x201c;Sanctioned Country&#x201d;); and the Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii) to fund or facilitate any activities of or business in any Sanctioned Country or (iii) in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions.  Since the Company&#x2019;s inception, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(mm)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No Restrictions on Subsidiaries</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  No subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary&#x2019;s capital stock or similar ownership interest, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#x2019;s properties or assets to the Company or any other subsidiary of the Company.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(nn)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No Broker&#x2019;s Fees.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against any of them or any Underwriter for a brokerage commission, finder&#x2019;s fee or like payment in connection with the offering and sale of the Shares.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(oo)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No Registration Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  No person has the right to require the Company or any of its subsidiaries to register any securities for sale under the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Shares, except for such rights as have been duly waived.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(pp)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No Stabilization.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Neither the Company nor any of its subsidiaries or, to the Company&#x2019;s knowledge, other affiliates has taken, directly or indirectly, without giving effect to activities by the Underwriters, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price of the Shares.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(qq)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Margin Rules</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Neither the issuance, sale and delivery of the Shares nor the application of the proceeds thereof by the Company as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(rr)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Forward-Looking Statements.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) included or incorporated by reference in any of the Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(ss)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Statistical and Market Data.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and market-related data included or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(tt)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sarbanes-Oxley Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  There is and has been no failure on the part of the Company or any of the Company&#x2019;s directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated in connection therewith (the &#x201c;Sarbanes-Oxley Act&#x201d;), including Section 402 related to loans and Sections 302 and 906 related to certifications.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(uu)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Status under the Securities Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">bona fide</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the Shares and at the date hereof, the Company was not and is not an &#x201c;ineligible issuer,&#x201d; as defined in Rule 405 under the Securities Act.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(vv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No Ratings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  There are (and prior to the Closing Date, will be) no debt securities, convertible securities or preferred stock issued or guaranteed by </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Company or any of its subsidiaries that are rated by a &#x201c;nationally recognized statistical rating organization&#x201d;, as such term is defined in Section 3(a)(62) under the Exchange Act.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(ww)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Regulatory Matters; Products and Product Candidates</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company (collectively with its subsidiaries) and except, in each case, as would not, individually or in the aggregate, have a Material Adverse Effect: (i) has operated and currently operates its business in compliance with all Health Care Laws (as defined below) applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, storage, import, export or disposal of any of the Company&#x2019;s or its subsidiaries&#x2019; product candidates or any product manufactured or distributed by the Company; (ii) has not received any FDA Form 483, written notice of adverse finding, warning letter, untitled letter or other correspondence or written notice from any court or arbitrator or governmental or regulatory authority alleging or asserting non-compliance with (A) any Health Care Laws or (B) any licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements or amendments thereto required by any such Health Care Laws (&#x201c;Regulatory Authorizations&#x201d;); (iii) possesses all Regulatory Authorizations required to conduct its business as currently conducted, and such Regulatory Authorizations are valid and in full force and effect and the Company is not in violation of any term of any such Regulatory Authorizations; (iv) has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the Food and Drug Administration (&#x201c;FDA&#x201d;), the Department of Health and Human Services or any comparable foreign or other regulatory authority to which they are subject (collectively, the &#x201c;Applicable Regulatory Authorities&#x201d;) alleging that any product of the Company is in violation of any Health Care Laws or Regulatory Authorizations and has no knowledge that the Applicable Regulatory Authorities or any other third party is threatening any such claim, litigation, arbitration, action, suit, investigation or proceeding; (v) has not received written notice that any of the Applicable Regulatory Authorities has taken, is taking or intends to take action to limit, suspend, or revoke any Regulatory Authorizations and has no knowledge that any of the Applicable Regulatory Authorities is considering such action; (vi) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws or Regulatory Authorizations and, to the knowledge of the Company, that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct on the date filed (or were materially corrected or supplemented by a subsequent submission); (vii) is not a party to and does not have any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred or non-prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or imposed by any Applicable Regulatory Authority; and (viii) along with its employees, officers and directors, has not been excluded, suspended or debarred from participation in any government health care program or human clinical research and, to the knowledge of the Company, is not subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term &#x201c;Health Care Laws&#x201d; means Title XVIII of the Social Security Act, 42 U.S.C. &#167;&#167; 1395-1395hhh (the Medicare statute); Title XIX of the Social Security Act, 42 U.S.C. &#167;&#167; 1396-1396v (the Medicaid statute); the Federal Anti-Kickback Statute, 42 U.S.C. &#167; 1320a-7b(b); the civil False Claims Act, 31 U.S.C. &#167;&#167; 3729 et seq.; the criminal False Claims Act, 42 U.S.C. 1320a-7b(a); any criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286, 287, 1347 and 1349, and the health care fraud criminal provisions under the Health Insurance Portability and Accountability Act of 1996, 42 U.S.C. &#167;&#167; 1320d et seq. (&#x201c;HIPAA&#x201d;); the Civil Monetary Penalties Law, 42 U.S.C. &#167;&#167; 1320a-7a and 1320a-7b; the Physician Payments Sunshine Act, 42 U.S.C. &#167; 1320a-7h; the Exclusion Statute, 42 U.S.C. &#167; 1320a-7; HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, 42 U.S.C. &#167;&#167; 17921 et seq.; the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. &#167;&#167; 301 et seq.; the regulations promulgated pursuant to such laws; and any similar federal, state and local laws and regulations.</font></p>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(xx)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Studies and Clinical Trials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. (i) Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the pre-clinical studies and clinical trials conducted by or, to the knowledge of the Company, on behalf of or sponsored by the Company, or in which the Company has participated that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or the results of which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, were, and if still pending are, being conducted in all respects in accordance with all applicable Health Care Laws; (ii) the descriptions in the Registration Statement, the Pricing Disclosure Package and the Prospectus of the results of such studies and trials are, to the knowledge of the Company, accurate and complete in all respects and fairly present the data derived therefrom; (iii) the Company has no knowledge of any other studies or trials not described in the Registration Statement, the Pricing Disclosure Package and the Prospectus the results of which are inconsistent with or which the Company reasonably believes call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and (iv) the Company has not received any written notices or correspondence from the regulatory authorities or any other governmental agency requiring or threatening the termination, modification or suspension of any pre-clinical studies or clinical trials that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or the results of which are referred to in the Registration Statement, </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Pricing Disclosure Package and the Prospectus other than ordinary course communications with respect to modifications in connection with the design and implementation of such studies or trials, and, to the Company&#x2019;s knowledge, there are no reasonable grounds for the same.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further Agreements of the Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company covenants and agrees with each Underwriter that:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Required Filings.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The Company will file the final Prospectus with the Commission within the time periods specified by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the Securities Act; and the Company will file promptly all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus is required in connection with the offering or sale of the Shares; and the Company will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered) to the Underwriters in New York City prior to 10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such quantities as the Representatives may reasonably request.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Delivery of Copies.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The Company will deliver, without charge, (i) to the Representatives, two signed copies of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and documents incorporated by reference therein; and (ii) to each Underwriter (A) a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B) during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including all amendments and supplements thereto and documents incorporated by reference therein and each Issuer Free Writing Prospectus) as the Representatives may reasonably request.  As used herein, the term &#x201c;Prospectus Delivery Period&#x201d; means such period of time after the first date of the public offering of the Shares as in the opinion of counsel for the Underwriters a prospectus relating to the Shares is required by law to be delivered (or required to be delivered but for Rule 172 under the Securities Act) in connection with sales of the Shares by any Underwriter or dealer.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amendments or Supplements, Issuer Free Writing Prospectuses.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Before making, preparing, using, authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company will furnish to the Representatives and counsel for the Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not make, prepare, use, authorize, approve, refer to or file any </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">such Issuer Free Writing Prospectus or file any such proposed amendment or supplement to which the Representatives reasonably object.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Notice to the Representatives.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The Company will advise the Representatives promptly, and confirm such advice in writing (which may be by electronic mail), (i) when the Registration Statement has become effective; (ii) when any amendment to the Registration Statement has been filed or becomes effective; (iii) when any supplement to the Pricing Disclosure Package, the Prospectus, any Issuer Free Writing Prospectus or any Written Testing-the-Waters Communication or any amendment to the Prospectus has been filed or distributed; (iv) of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or any other request by the Commission for any additional information including, but not limited to, any request for information concerning any Testing-the-Waters Communication; (v) of the issuance by the Commission or any other governmental or regulatory authority of any order suspending the effectiveness of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package, the Prospectus or any Written Testing-the-Waters Communication or the initiation or threatening of any proceeding for that purpose or pursuant to Section 8A of the Securities Act; (vi) of the occurrence of any event or development within the Prospectus Delivery Period as a result of which the Prospectus, any of the Pricing Disclosure Package, any Issuer Free Writing Prospectus or any Written Testing-the-Waters Communication as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus, the Pricing Disclosure Package,  any such Issuer Free Writing Prospectus or any Written Testing-the-Waters Communication is delivered to a purchaser, not misleading; and (vii) of the receipt by the Company of any notice with respect to any suspension of the qualification of the Shares for offer and sale in any jurisdiction or the initiation or, to the knowledge of the Company, threatening of any proceeding for such purpose; and the Company will use its reasonable best efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package or the Prospectus or any Written Testing-the-Waters Communication or suspending any such qualification of the Shares and, if any such order is issued, will obtain as soon as possible the withdrawal thereof.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Ongoing Compliance.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  (1) If during the Prospectus Delivery Period (i) any event or development shall occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prospectus is delivered to a purchaser, not misleading or (ii) it is necessary to amend or supplement the Prospectus to comply with law, the Company will as promptly as practicable notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c) above, file with the Commission and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments or supplements to the Prospectus (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Prospectus as so amended or supplemented (or any document to be filed with the Commission and incorporated by reference therein) will not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with law and (2) if at any time prior to the Closing Date (i) any event or development shall occur or condition shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or (ii) it is necessary to amend or supplement the Pricing Disclosure Package to comply with law, the Company will as promptly as practicable notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c) above, file with the Commission (to the extent required) and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments or supplements to the Pricing Disclosure Package (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Pricing Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, be misleading or so that the Pricing Disclosure Package will comply with law.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Blue Sky Compliance.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The Company will qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request and will continue such qualifications in effect so long as required for distribution of the Shares; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> that the Company shall not be required to (i) qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii) file any general consent to service of process in any such jurisdiction or (iii) subject itself to taxation in any such jurisdiction if it is not otherwise so subject.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(g)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Earning Statement.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will make generally available to its security holders and the Representatives as soon as practicable an earning statement that satisfies the provisions of Section 11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the &#x201c;effective date&#x201d; (as defined in Rule 158) of the Registration Statement; </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided that the Company will be deemed to have furnished such statements to its security holders and the Representatives to the extent they are filed on the Commission&#x2019;s Electronic Data Gathering, Analysis, and Retrieval System (&#x201c;EDGAR&#x201d;).</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(h)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clear Market.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  For a period of 60 days after the date of the Prospectus (the &#x201c;Restricted Period&#x201d;), the Company will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Commission a registration statement under the Securities Act relating to, any shares of Stock or any securities convertible into or exercisable or exchangeable for Stock, or publicly disclose the intention to undertake any of the foregoing, or (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or any such other securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise, without the prior written consent of Jefferies LLC and Cowen and Company, LLC, other than the Shares to be sold hereunder.</font></div></div>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The restrictions described above do not apply to (i) the issuance of shares of Stock or securities convertible into or exercisable for shares of Stock pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of pre-funded warrants, warrants or options (including net exercise) or the settlement of RSUs (including net settlement), in each case outstanding on the date of this Agreement and described in the Prospectus; (ii) grants of stock options, stock awards, restricted stock, RSUs, or other equity awards and the issuance of shares of Stock or securities convertible into or exercisable or exchangeable for shares of Stock (whether upon the exercise of stock options or otherwise) to the Company&#x2019;s employees, officers, directors, advisors, or consultants pursuant to the terms of an equity compensation plan in effect as of the Closing Date and described in the Prospectus, provided that such recipients enter into a lock-up agreement with the Underwriters; (iii) the issuance of up to 10% of the outstanding shares of Stock, or securities convertible into, exercisable for, or which are otherwise exchangeable for, Stock, immediately following the Closing Date, in acquisitions or other similar strategic transactions, provided that such recipients enter into a lock-up agreement with the Underwriters; (iv) the filing of any registration statement on Form S-8 relating to securities granted or to be granted pursuant to any plan in effect on the date of this Agreement and described in the Prospectus or any assumed benefit plan pursuant to an acquisition or similar strategic transaction; or (v) the filing of a registration statement on Form S-3 registering certain securities of the Company after the 30-day</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">period day following the date of the Prospectus, provided that (i) no sale of any shares of Stock or any securities convertible into or exercisable or exchangeable for shares of Stock shall be made under such registration statement</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">on Form S-3 during the Restricted Period and (ii) no prospectus supplement to such registration statement on Form S-3 shall be filed nor any other filing or public announcement of an intent to sell under such registration statement on Form S-3 shall be made during the Restricted Period with respect to the offering or proposed offering of any shares of Stock or any securities convertible into or exercisable or exchangeable for Stock.</font></p>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Proceeds.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The Company will apply the net proceeds from the sale of the Shares as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#x201c;Use of Proceeds&#x201d;.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(j)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No Stabilization.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Neither the Company nor its subsidiaries or affiliates will take, directly or indirectly, without giving effect to activities by the Underwriters, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price of the Stock.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(k)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exchange Listing.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The Company will use its reasonable best efforts to list for quotation the Shares on the Nasdaq Global Select Market (the &#x201c;Nasdaq Market&#x201d;).</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(l)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reports.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  So long as the Shares are outstanding, the Company will furnish to the Representatives, as soon as commercially reasonable after the date that they are available, copies of all reports or other communications (financial or other) furnished to holders of the Shares, and copies of any reports and financial statements furnished to or filed with the Commission or any national securities exchange or automatic quotation system; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the Company will be deemed to have furnished such reports and financial statements to the Representatives to the extent they are filed on EDGAR, or any successor to such system.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(m)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Record Retention</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(n)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Shelf Renewal</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. If immediately prior to the third anniversary (the &#x201c;Renewal Deadline&#x201d;) on the initial effective date of the Registration Statement, any of the Shares remain unsold by the Underwriters, the Company will, prior to the Renewal Deadline, file, if it has not already done so and is eligible to do so, a new automatic shelf registration statement relating to the Shares, in a form satisfactory to the Representatives. If the Company is not eligible to file an automatic shelf registration statement, the Company will, prior to the Renewal Deadline, if it has not already done so, file a new shelf registration statement relating to the Shares, in a form satisfactory to the Representatives, and will use its best efforts to cause such registration statement to be declared effective within 180 days after the Renewal Deadline. The Company will take all other action necessary or appropriate to permit the issuance and sale of the Shares to continue </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as contemplated in the expired registration statement relating to the Shares. References herein to the Registration Statement shall include such new automatic shelf registration statement or such new shelf registration statement, as the case may be.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(o)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Emerging Growth Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company will promptly notify the Representatives if the Company ceases to be an Emerging Growth Company at any time prior to the later of (i) completion of the distribution of Shares within the meaning of the Securities Act and (ii) completion of the 60-day Restricted Period referred to in Section 4(h) hereof.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Agreements of the Underwriters</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Each Underwriter hereby represents and agrees that:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It has not, and will not use, authorize use of, refer to or participate in the planning for use of, any &#x201c;free writing prospectus&#x201d;, as defined in Rule 405 under the Securities Act (which term includes use of any written information furnished to the Commission by the Company and not incorporated by reference into the Registration Statement and any press release issued by the Company) other than (i) a free writing prospectus that contains no &#x201c;issuer information&#x201d; (as defined in Rule 433(h)(2) under the Securities Act) that was not included (including through incorporation by reference) in the Preliminary Prospectus or a previously filed Issuer Free Writing Prospectus, (ii) any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section 3(c) or Section 4(c) above (including any electronic road show), or (iii) any free writing prospectus prepared by such Underwriter and approved by the Company in advance in writing (each such free writing prospectus referred to in clauses (i) or (iii), an &#x201c;Underwriter Free Writing Prospectus&#x201d;).</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It has not and will not, without the prior written consent of the Company, use any free writing prospectus that contains the final terms of the Shares unless such terms have previously been included in a free writing prospectus filed with the Commission; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> that Underwriters may use a term sheet substantially in the form of Annex C hereto without the consent of the Company; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">provided further</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> that any Underwriter using such term sheet shall notify the Company, and provide a copy of such term sheet to the Company, prior to, or substantially concurrently with, the first use of such term sheet.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is not subject to any pending proceeding under Section 8A of the Securities Act with respect to the offering (and will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conditions of Underwriters&#x2019; Obligations.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The obligation of each Underwriter to purchase the Underwritten Shares on the Closing Date or the Option Shares on the Additional Closing Date, as the case may be, as provided herein is subject to the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">performance by the Company of its covenants and other obligations hereunder and to the following additional conditions:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Registration Compliance; No Stop Order.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  No order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose or pursuant to Section 8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance with Section 4(a) hereof; and all requests by the Commission for additional information shall have been complied with to the reasonable satisfaction of the Representatives.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Representations and Warranties.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The representations and warranties of the Company contained herein shall be true and correct on the date hereof and on and as of the Closing Date or the Additional Closing Date, as the case may be; and the statements of the Company and its officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date or the Additional Closing Date, as the case may be.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No Material Adverse Change.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  No event or condition of a type described in Section 3(i) hereof shall have occurred or shall exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the Prospectus (excluding any amendment or supplement thereto) and the effect of which in the judgment of the Representatives makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Officers&#x2019; Certificate.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior executive officer of the Company who is satisfactory to the Representatives on behalf of the Company and not in their individual capacities (i) confirming that such officers have carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to the knowledge of such officers, the representations set forth in Sections 3(b) and 3(f) hereof are true and correct, (ii) confirming that the other representations and warranties of the Company in this Agreement are true and correct and that the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date or the Additional Closing Date, as the case may be, and (iii) to the effect set forth in paragraphs (a), (b) and (c) above.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comfort Letters.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  On the date of this Agreement and on the Closing Date or the Additional Closing Date, as the case may be, Ernst &amp; Young LLP shall have furnished to the Representatives, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, containing statements and information of the type customarily included in accountants&#x2019; &#x201c;comfort letters&#x201d; to underwriters with respect to the financial statements and certain financial information contained or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided, that the letter delivered on the Closing Date or the Additional Closing Date, as the case may be, shall use a &#x201c;cut-off&#x201d; date no more than two business days prior to such Closing Date or such Additional Closing Date, as the case may be.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Opinion and 10b-5 Statement of Counsel for the Company.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Latham &amp; Watkins LLP, counsel for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinion and 10b-5 statement, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(g)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Opinion of Intellectual Property Counsel for the Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Representatives shall have received an opinion, on and as of the Closing Date or the Additional Closing Date, as the case may be, of Cooley LLP, intellectual property counsel for the Company, addressed to the Underwriters and in form and substance satisfactory to the Representatives.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(h)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Opinion and 10b-5 Statement of Counsel for the Underwriters.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, an opinion and 10b-5 statement, addressed to the Underwriters, of Davis Polk &amp; Wardwell LLP, counsel for the Underwriters, with respect to such matters as the Representatives may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon such matters.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">No Legal Impediment to Issuance and Sale.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the Shares; and no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the Shares.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(j)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Good Standing</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory evidence of the good standing of the Company and its significant subsidiaries in their respective jurisdictions of organization and their good standing in such other jurisdictions as the Representatives may reasonably request, in each case in writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions. Notwithstanding the above, the Representatives agree and acknowledge that, to the extent requested, satisfactory evidence of good standing may not be readily, or entirely, available with respect to the Company&#x2019;s significant subsidiaries organized in the P.R.C. and the Company shall not be required to provide such evidence unless requested at least 10 business days prior to the Closing Date or the Additional Closing Date, as applicable.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(k)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exchange Listing.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The Shares to be delivered on the Closing Date or the Additional Closing Date, as the case may be, shall have been approved for listing on the Nasdaq Market, subject to official notice of issuance.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(l)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Lock-up Agreements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The &#x201c;lock-up&#x201d; agreements, each substantially in the form of Exhibit A hereto, between you and certain shareholders, officers and directors of the Company relating to sales and certain other dispositions of shares of Stock or certain other securities, delivered to you on or before the date hereof, shall be in full force and effect on the Closing Date or the Additional Closing Date, as the case may be.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(m)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Additional Documents.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  On or prior to the Closing Date or the Additional Closing Date, as the case may be, the Company shall have furnished to the Representatives such further certificates and documents as the Representatives may reasonably request.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All opinions, letters, certificates and evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indemnification and Contribution</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Indemnification of the Underwriters.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors and officers and each person, if any, who controls such Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, from and against any and all losses, claims, damages and liabilities (including, without limitation, legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred), joint or several, that arise out of, or are based upon, (i) any untrue statement or alleged untrue statement of a material fact contained or incorporated by reference in the Registration Statement or caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary in order to make the statements therein, not misleading, or (ii) any untrue statement or alleged untrue statement of a material fact contained or incorporated by reference in the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#x201c;issuer information&#x201d; filed or required to be filed pursuant to Rule 433(d) under the Securities Act, any Written Testing-the-Waters Communication, any road show as defined in Rule 433(h) under the Securities Act (a &#x201c;road show&#x201d;) or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), or caused by any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, in each case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in paragraph (b) below.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Indemnification of the Company.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a) above, but only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement, the Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any Written Testing-the-Waters Communication, any road show or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), it being understood and agreed upon that the only such information furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter:  the concession and reallowance figures appearing in the third paragraph under the caption &#x201c;Underwriting&#x201d;, the information contained in the sixteenth, seventeenth and eighteenth paragraphs under the caption &#x201c;Underwriting&#x201d;.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Notice and Procedures.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of this Section 7, such person (the &#x201c;Indemnified Person&#x201d;) shall promptly notify the person against whom such indemnification may be sought (the &#x201c;Indemnifying Person&#x201d;) in writing; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have under the preceding paragraphs of this Section 7 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">further</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that the failure to notify the Indemnifying Person shall not relieve it from any </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs of this Section 7.  If any such proceeding shall be brought or asserted against an Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel to the Indemnifying Person) to represent the Indemnified Person and any others entitled to indemnification pursuant to this Section that the Indemnifying Person may designate in such proceeding and shall pay the reasonable fees and expenses in such proceeding and shall pay the reasonable fees and expenses of such counsel related to such proceeding, as incurred.  In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless (i) the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii) the Indemnifying Person has failed within a reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii) the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the Indemnifying Person; or (iv) the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them.  It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred.  Any such separate firm for any Underwriter, its affiliates, directors and officers and any control persons of such Underwriter shall be designated in writing by the Representatives and any such separate firm for the Company, its directors, its officers who signed the Registration Statement and any control persons of the Company shall be designated in writing by the Company.  The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement.  Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by the Indemnifying Person of such request and (ii) the Indemnifying Person shall not have reimbursed the Indemni&#x1f;fied Person in accordance with such request prior to the date of such settlement.  No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such Indemnified Person, unless such settlement (x) includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of such proceeding and (y) does not include any</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contribution.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  If the indemnification provided for in paragraphs (a) or (b) above is unavailable to an Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters on the other, from the offering of the Shares or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) but also the relative fault of the Company, on the one hand, and the Underwriters on the other, in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations.  The relative benefits received by the Company, on the one hand, and the Underwriters on the other, shall be deemed to be in the same respective proportions as the net proceeds (before deducting expenses) received by the Company from the sale of the Shares and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate offering price of the Shares.  The relative fault of the Company, on the one hand, and the Underwriters on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties&#x2019; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Limitation on Liability.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to paragraph (d) above were determined by </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pro</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">rata</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in paragraph (d) above.  The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph (d) above shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such Indemnified Person in connection with any such action or claim.  Notwithstanding the provisions of paragraphs (d) and (e), in no event shall an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Shares exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission.  No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.  The Underwriters&#x2019; obligations to contribute pursuant </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to paragraphs (d) and (e) are several in proportion to their respective purchase obligations hereunder and not joint.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Non-Exclusive Remedies.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The remedies provided for in this Section 7 paragraphs (a) through (e) are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effectiveness of Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement shall become effective as of the date first written above.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement may be terminated in the absolute discretion of the Representatives, by notice to the Company, if after the execution and delivery of this Agreement and on or prior to the Closing Date or, in the case of the Option Shares, prior to the Additional Closing Date (i) trading generally shall have been suspended or materially limited on or by any of the New York Stock Exchange or The Nasdaq Stock Market; (ii) trading of any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any over-the-counter market; (iii) a general moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or (iv) there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, that, in the judgment of the Representatives, is material and adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Defaulting Underwriter</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If, on the Closing Date or the Additional Closing Date, as the case may be, any Underwriter defaults on its obligation to purchase the Shares that it has agreed to purchase hereunder on such date, the non-defaulting Underwriters may in their discretion arrange for the purchase of such Shares by other persons satisfactory to the Company on the terms contained in this Agreement.  If, within 36 hours after any such default by any Underwriter, the non-defaulting Underwriters do not arrange for the purchase of such Shares, then the Company shall be entitled to a further period of 36 hours within which to procure other persons satisfactory to the non-defaulting Underwriters to purchase such Shares on such terms.  If other persons become obligated or agree to purchase the Shares of a defaulting Underwriter, either the non&#x2011;defaulting Underwriters or the Company may postpone the Closing Date or the Additional Closing Date, as the case may be, for up to five full business days in order to effect any changes that in the opinion of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or arrangement, and the Company agrees to promptly prepare any amendment or supplement to the Registration Statement and the Prospectus that effects any such changes.  As used in this Agreement, the term &#x201c;Underwriter&#x201d; includes, for all purposes of this Agreement unless the context otherwise </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">requires, any person not listed in Schedule 1 hereto that, pursuant to this Section 10, purchases Shares that a defaulting Underwriter agreed but failed to purchase.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the non-defaulting Underwriters and the Company as provided in paragraph (a) above, the aggregate number of Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be, does not exceed one-eleventh of the aggregate number of Shares to be purchased on such date, then the Company shall have the right to require each non-defaulting Underwriter to purchase the number of Shares that such Underwriter agreed to purchase hereunder on such date plus such Underwriter&#x2019;s pro rata share (based on the number of Shares that such Underwriter agreed to purchase on such date) of the Shares of such defaulting Underwriter or Underwriters for which such arrangements have not been made.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the non-defaulting Underwriters and the Company as provided in paragraph (a) above, the aggregate number of Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be, exceeds one-eleventh of the aggregate amount of Shares to be purchased on such date, or if the Company shall not exercise the right described in paragraph (b) above, then this Agreement or, with respect to any Additional Closing Date, the obligation of the Underwriters to purchase Shares on the Additional Closing Date, as the case may be, shall terminate without liability on the part of the non-defaulting Underwriters.  Any termination of this Agreement pursuant to this Section 10 shall be without liability on the part of the Company, except that the Company will continue to be liable for the payment of expenses as set forth in Section 11 hereof and except that the provisions of Section 7 hereof shall not terminate and shall remain in effect.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nothing contained herein shall relieve a defaulting Underwriter of any liability it may have to the Company or any non-defaulting Underwriter for damages caused by its default.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payment of Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company will pay or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i) the costs incident to the authorization, issuance, sale, preparation and delivery of the Shares and any taxes payable in that connection; (ii) the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, the Preliminary Prospectus, any Issuer Free Writing Prospectus, any Pricing Disclosure Package and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii) the fees and expenses of the Company&#x2019;s counsel and independent accountants; (iv) the fees and expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the Shares under the laws of such jurisdictions as the Representatives may </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">designate and the preparation, printing and distribution of a Blue Sky Memorandum (including the related fees and expenses of counsel for the Underwriters); (v) the cost of preparing stock certificates; (vi) the costs and charges of any transfer agent and any registrar; (vii) all expenses and application fees incurred in connection with any filing with, and clearance of the offering by, FINRA; (viii) all expenses incurred by the Company in connection with any &#x201c;road show&#x201d; presentation to potential investors and (x) all fees and expenses related to the listing of the Shares on the Nasdaq Market; provided that the aggregate amount payable by the Company pursuant to clauses (iv) and (vii) (other than application fees paid by the Company directly to FINRA) shall not exceed $25,000.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If (i) this Agreement is terminated pursuant to Section 9, (ii) the Company for any reason fails to tender the Shares for delivery to the Underwriters or (iii) the Underwriters decline to purchase the Shares for any reason permitted under this Agreement, the Company agrees to reimburse the Underwriters for all out-of-pocket costs and expenses (including the fees and expenses of their counsel) reasonably incurred by the Underwriters in connection with this Agreement and the offering contemplated hereby. For the avoidance of doubt, it is understood that the Company shall not pay or reimburse any costs, fees or expenses incurred by any Underwriter that defaults on its obligations to purchase the Shares.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">12.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Persons Entitled to Benefit of Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Underwriter referred to in Section 7 hereof.  Nothing in this Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein.  No purchaser of Shares from any Underwriter shall be deemed to be a successor merely by reason of such purchase.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">13.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Survival</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The respective indemnities, rights of contribution, representations, warranties and agreements of the Company and the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant hereto shall survive the delivery of and payment for the Shares and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters or the directors, officers, controlling persons or affiliates referred to in Section 7 hereof.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">14.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Defined Terms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  For purposes of this Agreement, (a) except where otherwise expressly provided, the term &#x201c;affiliate&#x201d; has the meaning set forth in Rule 405 under the Securities Act; (b) the term &#x201c;business day&#x201d; means any day other than a day on which banks are permitted or required to be closed in New York City; and (c) the term &#x201c;subsidiary&#x201d; has the meaning set forth in Rule 405 under the Securities Act; and (d) the term &#x201c;significant subsidiary&#x201d; has the meaning set forth in Rule 1-02 of Regulation S-X under the Exchange Act. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">15.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compliance with USA Patriot Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">16.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Miscellaneous</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Notices.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted and confirmed by any standard form of telecommunication.  Notices to the Underwriters shall be given to the Representatives c/o Jefferies LLC, 520 Madison Avenue, New York, New York 10022, Attention: General Counsel, and Cowen and Company, LLC, Attention: Head of Equity Capital Markets (fax: (646) 562-1249), with a copy to the General Counsel (fax: (646) 562-1124).  Notices to the Company shall be given to it at Terns Pharmaceuticals, Inc., 1065 East Hillsdale, Suite 100, Attention: Chief Executive Officer and General Counsel, and a copy (which shall not constitute notice) to Latham &amp; Watkins LLP, 140 Scott Drive, Menlo Park, California 94025, Attention: Brian Cuneo.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Governing Law.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by and construed in accordance with the laws of the State of New York. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Waiver of Jury Trial.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Each of the parties hereto hereby waives any right to trial by jury in any suit or proceeding arising out of or relating to this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recognition of the U.S. Special Resolution Regimes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </font></div></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(i) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(ii) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As used in this Section 16(g):</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;BHC Act Affiliate&#x201d; has the meaning assigned to the term &#x201c;affiliate&#x201d; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Covered Entity&#x201d; means any of the following:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:16.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(i) a &#x201c;covered entity&#x201d; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b);</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:16.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(ii) a &#x201c;covered bank&#x201d; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:16.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(iii) a &#x201c;covered FSI&#x201d; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Default Right&#x201d; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;U.S. Special Resolution Regime&#x201d; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Counterparts.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  This Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The words &#x201c;execution,&#x201d; &#x201c;signed,&#x201d; &#x201c;signature,&#x201d; and words of like import in this Agreement or in any other certificate, agreement or document related to this Agreement, if any, shall include images of manually executed signatures transmitted by facsimile or other electronic format (including, without limitation, &#x201c;pdf,&#x201d; &#x201c;tif&#x201d; or &#x201c;jpg&#x201d;) and other electronic signatures (including, without limitation, DocuSign and AdobeSign). The use of electronic signatures and electronic records (including, without limitation, any contract or other record created, generated, sent, communicated, received, or stored by electronic means) shall be of the same legal effect, validity and enforceability as a manually executed signature or use of a paper-based record-keeping system to the fullest extent permitted by applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act and any other applicable law, including, without limitation, any state law based on the Uniform Electronic Transactions Act or the Uniform Commercial Code.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amendments or Waivers.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(g)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Headings.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the meaning or interpretation of, this Agreement.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the foregoing is in accordance with your understanding, please indicate your acceptance of this Agreement by signing in the space provided below.</font></p>
  <p style="margin-left:45.0%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Very truly yours,</font></p>
  <p style="margin-left:45.0%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TERNS PHARMACEUTICALS, INC.</font></p>
  <p style="margin-left:45.0%;text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Mark Vignola	<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">      Name: Mark Vignola<br>      Title: CFO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accepted:  As of the date first written above</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JEFFERIES LLC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COWEN AND COMPANY, LLC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For themselves and on behalf of the<br>several Underwriters listed<br>in Schedule 1 hereto.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JEFFERIES LLC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Matthew Kim	<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	Name: Matthew Kim<br>	Title: Managing Director, Joint US</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                  Head of Biopharmaceuticals</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                                                                 	   </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COWEN AND COMPANY, LLC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Tanya Joseph	<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	Name: Tanya Joseph<br>	Title: Managing Director</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule 1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:35.382%;"></td>
    <td style="width:32.315%;"></td>
    <td style="width:32.303%;"></td>
   </tr>
   <tr style="height:22.3pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Underwriter</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jefferies LLC</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,140,000</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cowen and Company, LLC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,363,750</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UBS Securities LLC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,086,750</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mizuho Securities USA LLC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">931,500</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JMP Securities LLC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">828,000</font></p></td>
   </tr>
   <tr style="height:23.05pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,350,000</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annex A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pricing Disclosure Package</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">b.  	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pricing Information Provided Orally by Underwriters</font></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Underwritten Shares: 10,350,000</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option Shares: 1,552,500</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Public Offering Price Per Share: $7.25</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annex B</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Written Testing-the-Waters Communications<br><br>None.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annex C</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Terns Pharmaceuticals, Inc.<br><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pricing Term Sheet</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br><br>None.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM OF LOCK-UP AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> [</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Symbol&quot;, serif;min-width:fit-content;">&#xf0b7;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jefferies LLC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cowen and Company, LLC<br><br>As Representatives of <br>the several Underwriters listed in <br>Schedule 1 to the Underwriting<br>Agreement referred to below</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">c/o Jefferies LLC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">520 Madison Avenue</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">New York, New York 10022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">c/o Cowen and Company, LLC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">599 Lexington Avenue</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">New York, New York 10022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Re:	Terns Pharmaceuticals, Inc. --- Public Offering</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ladies and Gentlemen:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The undersigned understands that you, each as one of several representatives (the &#x201c;Representatives&#x201d;) of the several Underwriters, propose to enter into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with Terns Pharmaceuticals, Inc., a Delaware corporation (the &#x201c;Company&#x201d;), providing for the public offering (the &#x201c;Public Offering&#x201d;) by the several Underwriters named in Schedule 1 to the Underwriting Agreement (the &#x201c;Underwriters&#x201d;), of common stock, par value $0.0001 per share (&#x201c;Common Stock&#x201d;) (the &#x201c;Securities&#x201d;). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that there are no additional Underwriters other than you listed on Schedule 1 to the Underwriting Agreement, all references to the Representatives and the Underwriters shall refer to you, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. To the extent only one Representative is listed above, all references to the term Representatives shall mean Representative in the singular form.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In consideration of the Underwriters&#x2019; agreement to purchase and make the Public Offering of the Securities, and for other good and valuable consideration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of the Representatives on behalf of the Underwriters, the undersigned will not, and will not cause any direct or indirect affiliate to, during the period beginning on the date of this letter agreement (this &#x201c;Letter Agreement&#x201d;) and ending at the close of business 60 days after the date of the final prospectus relating to the Public Offering (the &#x201c;Prospectus&#x201d;) (such period, the &#x201c;Restricted Period&#x201d;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock (including without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise of a stock option or warrant) (collectively with the Common Stock, &#x201c;Lock-Up Securities&#x201d;),   (2) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the Lock-Up Securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Lock-Up Securities, in cash or otherwise, (3) make any demand for or exercise any right with respect to the registration of any Lock-Up Securities, or (4) publicly disclose the intention to do any of the foregoing.  The undersigned acknowledges and agrees that the foregoing precludes the undersigned from engaging in any hedging or other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition or transfer (whether by the undersigned or any other person) of any economic consequences of ownership, in whole or in part, directly or indirectly, of any Lock-Up Securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of Lock-Up Securities, in cash or otherwise.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notwithstanding the foregoing, the undersigned may:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)  transfer or dispose of the undersigned&#x2019;s Lock-Up Securities:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(i) as a bona fide gift or gifts, or for bona fide estate planning purposes,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(ii) by will, other testamentary document or intestacy,</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(iii) to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned, or if the undersigned is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust (for purposes of this Letter Agreement, &#x201c;immediate family&#x201d; shall mean any relationship by blood, current or former marriage, domestic partnership or adoption, not more remote than first cousin),</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(iv) to a partnership, limited liability company or other entity of which the undersigned and the immediate family of the undersigned are the legal and beneficial owner of all of the outstanding equity securities or similar interests,</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(v) to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i) through (iv) above,</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(vi) if the undersigned is a corporation, partnership, limited liability company, trust or other business entity, (A) to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control with the undersigned or affiliates of the undersigned (including, for the avoidance of doubt, where the undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B) as part of a distribution to members, partners,  shareholders or other equity holders of the undersigned,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(vii) by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree, separation agreement or other court order,</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(viii) to the Company from an employee or other service provider of the Company upon death, disability or termination of employment or service, in each case, of such employee or service provider,</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(ix)  as part of a sale of the undersigned&#x2019;s Lock-Up Securities acquired (A) in open market transactions after the closing date for the Public Offering or (B) from the Underwriters in the Public Offering,</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(x) to the Company in connection with the vesting, settlement, or exercise of restricted stock units, options, warrants or other rights to purchase shares of Common Stock (including, in each case, by way of &#x201c;net&#x201d; or &#x201c;cashless&#x201d; exercise), including for the payment of exercise price and tax and remittance payments due as a result of the vesting, settlement, or exercise of such restricted stock units, options, warrants or rights, provided that any such shares of Common Stock received upon such exercise, vesting or settlement shall be subject to the terms of this Letter Agreement, and provided further that any such restricted stock units, options, warrants or rights are held by the undersigned pursuant to an agreement or equity awards granted under a stock incentive plan or other equity award plan, each such agreement or plan which is described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, or filed as an exhibit to the Registration Statement, or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(xi) pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by the Board of Directors of the Company and made to all holders of the Company&#x2019;s capital stock involving a Change of Control (as defined below) of the Company (for purposes hereof, &#x201c;Change of Control&#x201d; shall mean the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of shares of capital stock if, after such transfer, such person or group of affiliated persons would hold more than 50% of the outstanding voting securities of the Company (or the surviving entity)); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> that in the event that such tender offer, merger, consolidation or other similar transaction is not completed, the undersigned&#x2019;s Lock-Up Securities shall remain subject to the provisions of this Letter Agreement;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> that (A) in the case of any transfer, distribution or other disposition pursuant to clause (a)(i), (ii), (iii), (iv), (v), (vi) and (vii), such transfer shall not involve a disposition for value and each donee, devisee, transferee or distributee shall execute and deliver to the Representatives a lock-up letter in the form of this Letter Agreement, (B) in the case of any transfer, distribution or disposition pursuant to clauses (a)(i), (ii), (iii), (iv), (v), (vi), and (x), no filing by any party (donor, donee, devisee, transferor, transferee, distributer or distributee) under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on a Form 5 made after the expiration of the Restricted Period referred to above) and (C) in the case of any transfer or distribution pursuant to clauses (a)(vii) and (viii) it shall be a condition to such transfer that no public filing, report or announcement shall be voluntarily made and if any filing under Section 16(a) of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of Common Stock in connection with such transfer or distribution shall be legally required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b)  exercise outstanding options, settle restricted stock units or other equity awards or exercise warrants pursuant to plans described in the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided that any Lock-up Securities received upon such exercise, vesting or settlement shall be subject to the terms of this Letter Agreement;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(c) convert outstanding preferred stock, pre-funded warrants to acquire Common Stock, warrants to acquire preferred stock or convertible securities into shares of Common Stock or warrants to acquire shares of Common Stock; provided that any such shares of Common Stock or warrants received upon such conversion shall be subject to the terms of this Letter Agreement;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(d) establish or amend existing trading plans pursuant to Rule 10b5-1 under the Exchange Act for the transfer or disposition of shares of Lock-Up Securities; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> that (1) such plans do not provide for the transfer or disposition of Lock-Up Securities during the Restricted Period and (2) no filing by any party under the Exchange Act or other public announcement shall be required or made voluntarily in connection with such trading plan during the Restricted Period in contravention of this Lock-Up Agreement; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(e) sell Lock-Up Securities under existing trading plans pursuant to Rule 10b5-1 under the Exchange Act; provided that any filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the undersigned is not a natural person, the undersigned represents and warrants that no single natural person, entity or &#x201c;group&#x201d; (within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)) beneficially owns, directly or indirectly, 50% or more of the common equity interests, or 50% or more of the voting power, in the undersigned.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In furtherance of the foregoing, the Company, and any duly appointed transfer agent for the registration or transfer of the securities described herein, are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Letter Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Letter Agreement.  All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the Underwriters solicited any action from the undersigned with respect to the Public Offering of the Securities and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate. The undersigned further acknowledges and agrees that, although the Representatives may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with the Public Offering, the Representatives and the other Underwriters are not making a recommendation to you to enter into this Letter Agreement, and nothing set forth in such disclosures is intended to suggest that the Representatives or any Underwriter is making such a recommendation.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The undersigned understands that, if either (i) the Representatives, on the one hand, or the Company, on the other hand, informs the other, prior to the execution of the Underwriting Agreement, that it has determined not to proceed with the Public Offering, (ii) the Registration Statement is withdrawn, prior to the execution of the Underwriting Agreement, (iii) the Underwriting Agreement does not become effective by February 1, 2023, (iv) the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold thereunder, or (v) the Restricted Period has expired, this Letter Agreement shall automatically terminate and be of no further force and effect and the undersigned shall be released from all obligations under this Letter Agreement.  The undersigned understands that the Underwriters are entering into the Underwriting Agreement and proceeding with the Public Offering in reliance upon this Letter Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Letter Agreement and any claim, controversy or dispute arising under or related to this Letter Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to conflict of law principles thereof.</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Very truly yours,</font></p>
  <p style="margin-left:40.0%;text-indent:11.111%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="margin-left:40.0%;text-indent:11.111%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="margin-left:40.0%;text-indent:11.111%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="margin-left:40.0%;text-indent:11.111%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: ______________________</font></p>
  <p style="margin-left:40.0%;text-indent:11.111%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:40.0%;text-indent:11.111%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tern-ex5_1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<html>
 <head>
  <title>EX-5.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 5.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img60210087_0.jpg" alt="img60210087_0.jpg" style="width:289px;height:69px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img60210087_1.jpg" alt="img60210087_1.jpg" style="width:232px;height:16px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img60210087_2.jpg" alt="img60210087_2.jpg" style="width:288px;height:277px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 23, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Terns Pharmaceuticals, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1065 East Hillsdale Blvd.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foster City, California 94404</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	Re:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement on Form S-3 (No. 333-263370); 11,902,500 shares of common stock, $0.0001 par value per share.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the addressee set forth above:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have acted as special counsel to Terns Pharmaceuticals, Inc., a Delaware corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), in connection with the proposed issuance of 11,902,500 shares of common stock, $0.0001 par value per share (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). The Shares are included in a registration statement on Form S-3 under the Securities Act of 1933, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), filed with the Securities and Exchange Commission (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Commission</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) on March 8, 2022 (Registration No. 333-263370) (as amended, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Registration Statement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and are being offered pursuant to a base prospectus dated March 14, 2022 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Base Prospectus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and a prospectus supplement dated December 20, 2022 filed with the Commission pursuant to Rule 424(b) under the Act (together with the Base Prospectus, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prospectus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  The Shares are being sold pursuant to an underwriting agreement dated December 20, 2022 among the Company and Jefferies LLC and Cowen and Company, LLC, as representatives of the several underwriters named in Schedule 1 thereto (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Underwriting Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the Prospectus, other than as expressly stated herein with respect to the issue of the Shares.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:27.35pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 23, 2022</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.65pt;font-family:Times New Roman;margin-bottom:18.0pt;text-align:left;"><img src="img60210087_3.jpg" alt="img60210087_3.jpg" style="width:162px;height:11px;">&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">DGCL</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), and we express no opinion with respect to any other laws.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by the Underwriting Agreement, the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable.  In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our opinions are subject to: (i) the effect of bankruptcy, insolvency, reorganization, preference, fraudulent transfer, moratorium or other similar laws relating to or affecting the rights and remedies of creditors; (ii) (a) the effect of general principles of equity, whether considered in a proceeding in equity or at law (including the possible unavailability of specific performance or injunctive relief), (b) concepts of materiality, reasonableness, good faith and fair dealing, and (c) the discretion of the court before which a proceeding is brought; and (iii) the invalidity under certain circumstances under law or court decisions of provisions providing for the indemnification of or contribution to a party with respect to a liability where such indemnification or contribution is contrary to public policy.  We express no opinion as to (a) any provision for liquidated damages, default interest, late charges, monetary penalties, make-whole premiums or other economic remedies to the extent such provisions are deemed to constitute a penalty; (b) consents to, or restrictions upon, governing law, jurisdiction, venue, arbitration, remedies, or judicial relief; (c) any provision requiring the payment of attorneys&#x2019; fees, where such payment is contrary to law or public policy; (d) other applicable exceptions; and (e) the severability, if invalid, of provisions to the foregoing effect.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:27.35pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 23, 2022</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.65pt;font-family:Times New Roman;margin-bottom:18.0pt;text-align:left;"><img src="img60210087_3.jpg" alt="img60210087_3.jpg" style="width:162px;height:11px;">&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act.  We consent to your filing this opinion as an exhibit to the Company&#x2019;s Current Report on Form 8-K dated December 23, 2022 and to the reference to our firm in the Prospectus under the heading &#x201c;Legal Matters.&#x201d;  In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sincerely,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Latham &amp; Watkins LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>tern-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.38%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img52906712_0.jpg" alt="img52906712_0.jpg" style="width:198px;height:73px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="margin-left:1.107%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Terns Announces Pricing of $75 Million Public Offering</font></p>
  <p style="margin-left:1.107%;text-indent:0.0%;font-size:10.0pt;margin-top:9.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 21, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="margin-left:1.107%;text-indent:0.0%;font-size:10.0pt;margin-top:7.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FOSTER CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (&#x201c;Terns&#x201d; or the &#x201c;Company&#x201d;) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced the pricing of its underwritten public offering of 10,350,000 shares of its common stock at a public offering price of $7.25 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected to be approximately $75.0 million, excluding any exercise of the underwriters&#x2019; option to purchase additional shares. In addition, Terns has granted the underwriters a 30-day option to purchase up to an additional 1,552,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 23, 2022, subject to customary closing conditions. All of the securities are being offered by Terns.</font></p>
  <p style="margin-left:1.107%;text-indent:0.0%;font-size:10.0pt;margin-top:7.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Jefferies and Cowen are acting as lead book-running managers for the proposed offering. UBS Investment Bank is also acting as a bookrunner for the proposed offering. Mizuho and JMP Securities, a Citizens Company, are acting as co-lead managers for the proposed offering.</font></p>
  <p style="margin-left:1.107%;text-indent:0.0%;font-size:10.0pt;margin-top:7.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Terns intends to use the net proceeds from the proposed offering, together with its existing cash and cash equivalents, to advance its clinical-stage development pipeline, including the TERN-501, TERN-701 and TERN-601 clinical programs and for working capital and general corporate purposes.</font></p>
  <p style="margin-left:1.107%;text-indent:0.0%;font-size:10.0pt;margin-top:7.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The public offering is being made pursuant to a registration statement on Form S-3 previously filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;), which became effective on March 14, 2022. A prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC&#x2019;s website located at </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">www.sec.gov.</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Copies of the prospectus supplement and accompanying prospectus relating to this offering, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at 877-821-7388 or by email at </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">prospectus_department@jefferies.com</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at 1-833-297-2926 or by e-mail: </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PostSaleManualRequests@broadridge.com.</font></font></p>
  <p style="margin-left:1.107%;text-indent:0.0%;font-size:10.0pt;margin-top:7.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification of these securities under the securities laws of any such state or other jurisdiction.</font></p>
  <p style="margin-left:1.107%;text-indent:0.0%;font-size:10.0pt;margin-top:7.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">About Terns Pharmaceuticals</font></p>
  <p style="margin-left:1.107%;text-indent:0.0%;font-size:10.0pt;margin-top:7.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and NASH. Terns&#x2019; pipeline includes four clinical stage development programs including an allosteric BCR-ABL inhibitor, a THR-&#x3b2; agonist, an FXR agonist, a VAP-1 inhibitor, and a preclinical small-molecule GLP-1 receptor agonist program.</font></p>
  <p style="margin-left:1.107%;text-indent:0.0%;font-size:10.0pt;margin-top:7.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cautionary Note Regarding Forward-Looking Statements</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="margin-left:0.973%;text-indent:0.138%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.083%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This press release contains forward-looking statements about Terns Pharmaceuticals, Inc. (the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) within the meaning of the federal securities laws, including those related to completion of the public offering. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#x201c;aim,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;assume,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;design,&#x201d; &#x201c;due,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;goal,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;objective,&#x201d; &#x201c;plan,&#x201d; &#x201c;positioned,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; &#x201c;would&#x201d; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company&#x2019;s plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Company&#x2019;s current and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company and the offering, please refer to the risk factors identified in the Company&#x2019;s SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2021 and its Quarterly Report on Form 10-Q for the period ended September 30, 2022, and its prospectus supplement. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.</font></p>
  <p style="margin-left:1.107%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:79.407%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Contacts for Terns</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:1.107%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:79.407%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Investors</font></p>
  <p style="margin-left:1.107%;text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Justin Ng</font></p>
  <p style="margin-left:1.107%;text-indent:0.0%;font-size:10.0pt;margin-top:0.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">investors@ternspharma.com</font></font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"></font>&#160;</p>
  <p style="margin-left:1.107%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Media</font></p>
  <p style="margin-left:1.107%;text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Jenna Urban</font></p>
  <p style="margin-left:1.107%;text-indent:0.0%;font-size:10.0pt;margin-top:0.8pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:59.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Berry &amp; Company Public Relations</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:1.107%;text-indent:0.0%;font-size:10.0pt;margin-top:0.8pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:59.537%;text-align:left;"><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">media@ternspharma.com</font></font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img52906712_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img52906712_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !) ,8# 2(  A$! Q$!_\0
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MPLG:X^&VC:3Y@,<=U>6UZB*Y!Q]_:&/!.W/.*T?V8"1_P5#^)F#C-SKP/O\
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M5+BWFN=%DCFB8,CJ8G(92."".017UY^VM^S-#^TE\)IK6QCC3QCHV^]T.X?
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MVV_["]M_)Z]_KY__ &W&"?!N!F.%&KVY)_X#)7LY-_R,:'^)'SO$7_(IQ/\
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M*E",_B5SW+Q#X>TOQ9HE[H^M:?;:KI5[&8;FRO(A)%*AZJRG@BOGN7_@G/\
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%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img60210087_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img60210087_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !S >$# 2(  A$! Q$!_\0
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M)HXY" LLMM(B'/3YF4#GZT :=%%1PS+.F] X&2/GC9#Q[$ T 24444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5@
M^+K&WN-!NKB:/?)!$QCRQPI/?'3/O6]4-U:PWMK);7";X9%VNN2,CZB@#$O[
MB8:3I]G''<".YC59YH87D,<>T9QM!PQZ#TZ]JP(WB70;N"".1+9-8&Y6B95$
M?F# .1[#CJ.]=]'&L4:1H,(@"J/0"JPTNR%M<V_V=3#<NTDJ,20S-U//3\*
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M.SGW9B2?SH LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M# I\XL,?,?8\\YH =K^L2:1I\DL%I)/+L9E(4^6F.[MV'MU/ZUHVLK3VD,K
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MIO+F2:\D"S[Y6*.&4G[N=HQ@= *Z^J8TJR$5I$(?DLR&@&X_(0,#OSQZU<H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img60210087_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img60210087_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ^ Z(# 2(  A$! Q$!_\0
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M_P +J\>?]#GKG_@?)_C7[4ZQ^SS\-/$6KWFJZGX(T6^U&\D\ZXNKBT5GE?\
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M\7/V=_#FHWMRUUJ]@&TV^DD;<[21' 9O<H4/XU^+?EL$#E6V$X#8X^E?=_\
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MXI^+?$<C[_[2U.>=3_L%R$_\= K/-JKA2C%/5L[/#S 1Q6/J5ZD;QA'KW?\
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MXC$5*T592DW][N%%(3MYH!##CD5H<@M%%(6"]3B@!:*** "BF[U]:4,&Z'-
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M_@?YH]X_X)+_ .I^(O\ OVG\I*_0VOSR_P""2_\ J?B+_OVG\I*_0VNG+?\
M=8?UU/&XT_Y'V(^7_I*"BBBO2/B#/\0?\@+4?^O:3_T U_/OJ7_(0O/^NTG_
M *$:_H(\0?\ ("U'_KVD_P#0#7\_&H_\A&\_Z[2?^A&OF<Y_Y=_/]#]R\,]\
M5_V[^I^OOP3^*^A?!3]AWP;XM\0S^78V6D+MB4CS+B4LP2)!W9CQ^9Z"ORQ^
M,WQ?U[XX?$#4O%OB*;_2;EML-LK$QVD /R0I[ =^Y)/>M7XH?'#4OB+X+\#>
M$5C:P\/>$]/6UAM/,+>=<'/F7#^YS@#L,^IKVS_@GC^SOH'QB\?WGB#Q%>VE
MS9>&WCF3068&6YE/*2.O>)2/Q; /'7CJUIXZ4,-2V5CZ+ 9=A^%Z&)SK&J]2
M3D^]DWHEYO2[/?O^">W[(3>"]/MOB=XRL2GB"\CSH^GW"<V,##_7,#TD<'C^
MZI]3Q]TT@  P.!2U]50HPP\%3@?@6:YIB,WQ4L7B'J^G1+HD%%%%=!Y!ROQ6
M_P"28>+O^P3=?^B6K\!5_P"/4?[E?OU\5O\ DF'B[_L$W7_HEJ_ 5?\ CU'^
MY7R^<_% _=_#7^%BO6/ZG[J?LO\ _)N_P[_[ MM_Z *]0KR_]E__ )-W^'?_
M &!;;_T 5ZA7T='^''T1^+YA_OE;_%+\V%?F)_P5>_Y*CX)_[!,W_HVOT[K\
MQ/\ @J]_R5'P3_V"9O\ T;7GYI_NLOD?8\"_\CVEZ2_(X7]BGX;GXV>#?C-X
M!+QJ^H:1;7=HS@9CNXI28F![#)P?8U\O:AI]UI&H75A?0-;7MK*T%Q!(,,DB
MDJRGZ$&OMC_@E#,J_%KQK&0=[Z+&0<<<3KG^8H_X*8?L]CPCXNMOB9H]MLTG
M7)!;ZH(Q\L-YCY9#Z"0#_OI?>OGYX=U,%"M'>-[^ES]<P^<1P?$N(RZL[1J\
MKC_BY5^:_(]/_P""9O[1 \1>&Y_A9K5SNU+2(S<:0\AYEM<_-$/>,G(_V6]J
M^[Z_ #X?^.-7^&?C31O%.A3&#5M*N%N(3_"^/O1MZJPRI'H:_<OX._%/2/C1
M\-]$\8:*^;34H [Q9RT$HXDB;W5@1^&>]>UE>*]M3]G+>/Y'YIQWD7]G8SZ[
M17[NK^$NOW[_ 'GY*?M[?\G7>-_]ZW_]$)7UO_P2>_Y)CXV_[#$?_HH5\H?\
M% (4@_:N\8[,_.MJYSZF!*^K_P#@D]_R3'QM_P!AB/\ ]%"O/PO_ ",9>K/L
M<^=^#:/^&G^A]T4445]6?SZ?B;^VGH5UX?\ VH/'\5TA4W%]]KC)&-T<B*RG
M]?TKUC_@G=^TQH7P9\2:OX5\5W*Z=HFOR1RP:E)Q'!<J-N)#_"K#'S= 0,]:
M^I?VYOV/9_CYIEMXH\*"&/QKID)B-O*0B:A ,D1EOX74D[2>.2#V(_*;Q!X=
MU3PGK-SH^MZ;=:1JENQ2:QOHC'(A]P>H]QQ7QE>%7 XGVT5I?\S^F,IQ& XJ
MR..75)6FHI-=4XVLUY:7_ _H(M;N"^MXKBVFCN+>5=R2Q.&5@>X(X(J:OPT^
M$/[3WQ)^"+QQ^&/$=Q'IJ')TJ\_?VI]MC?=_X#BOO7X _P#!2[POX\O+31/'
M]DG@_5IF$<>H(Y>PE8\ ,QYB)_VLCGK7N8?,Z-:T9>ZS\KSC@?,LL4JM)>UI
MKJM_FO\ *Y]K44R.19HU=&5T8!E93D$'N/:GUZY^=GD_[5EU/8_LX_$*>UN)
MK6>/2962:!RCH>.0PY!KRW_@FWJU_K/[-\5QJ-]<ZA<?VI<KYMU,TKX!7 RQ
M)Q7I_P"UK_R;5\1O^P/-_(5Y-_P3'_Y-GA_["MU_-:\V3_VR*_NO\S[2A%?Z
MM5I6U]K'_P!)/K2O@C_@IIKVJZ+XD^%JZ=JM]IRS7,@D6TN'B#_/'UVD9_'U
MK[WK\^O^"H__ ",_PG_Z^I?_ $.*GF%UAY6\OS(X1BI9Q24E?27_ *2S[]L<
M_8K?))/EKR?I5BH+'_CQM_\ KFO\A4]>@CY"6[/RK\#?#C7?VA/VL?B;X2D^
M(&O^'+6RNKV\B>SN9'^[.$";=X 'S?I7<?%OX _&#]D70_\ A87@GXG:KXET
MW3G1]2L]0=CM0G&YHV9E=,D ]",Y%<S\ OBMX3^#_P"VM\5]:\8ZS%H>G227
MUO%/,C,'D-RK;?E!.< UZ7^V%^W%X$\9?";4? _@"]D\4ZUXB5;1FMX'"0QE
M@3C(!9VP%"@'KGM7S4%1]C*<I6G=VUU\C]PQ-3,_[2P^&HTN;#N,.9."Y;->
M]=V[>9UNA?\ !3;P!<:)I\NIV5U;ZE);QM<PQ<HDI4%U!] V117S]H/_  3!
M\;:GH>G7EUJ-M875Q;1S2VLCC="[*"R'W!)'X452K9C;X#GEEO!?,_\ :'][
M_P CXJ/W:_;G]C7_ )-?^'7_ &#!_P"AM7XC'[M?MS^QK_R:_P##K_L&#_T-
MJYLF_BR]/U/=\2O^1?0_Q_\ MK/9Z***^M/YX"BBB@ K\J/^"G?Q1/BSXTZ?
MX3MIMUAX9M/WBJ>#=389LCU"!!^)K]0_$WB"U\*>'-4UJ^<16>GVTEU,Q[*B
MEC_*OP4\?^,+KX@>.->\27K%[G5;V6[8MU&YB0/P&!^%>#F];DI*FNI^M>'>
M6_6,?/&S6E-:?XG_ )*_WGV7_P $M_AE%<>+_$7Q$U(QPVNFP_V7I\DSA<S2
M?-*1GT0 ?\#K])_[:T__ )_K;_O\O^-?@!#:ZW%"JPP:G'"WSA8TE"G/?CC\
M:?\ 9]?_ .>>K_E-7GX7,/JU)4U3/K\\X.>=8Z>,GBTKV25MDNFY^@__  5+
M^&\&M>'_  U\0=-:&X?3G.F7[12*2(I"6B) /9MX_P"!"OD/]D?XG_\ "I?V
M@?">MRR^582W'V"\/;R9OD)/T)4_A7FC6>O7"&)H-5E1NL;1RL#^!%97S*V5
M)5E.0>X-<%;$<]=5XQL]#ZS*\F^K93+*JU55(VDKI6T?3=G]#H(89'(I:\=_
M9)^*2_%_X ^%-=>7S;^.W%C?>HGB^1L^Y #?\"KV*ONH352*FMF?RGBL//"5
MYX>I\46T_D%%%%6<Q^*7[;W_ "=-X^_Z_5_]%K7V?_P2F_Y)'XL_[# _]%+7
MQA^V]_R=-X^_Z_5_]%K7V?\ \$IO^21^+/\ L,#_ -%+7R.#_P"1A+YG]#\2
M?\DA1_PT_P!#[>HHHKZX_G@*^3/^"G/_ ";#+_V&;/\ F]?6=?)G_!3G_DV&
M7_L,V?\ -ZX\9_N\_0^CX<_Y'&%_QK\S\POA#H%AXJ^*OA#1M4B:?3=0U6WM
MKF)6*EXV<!@".G%?JPW_  3J^!S,3_PC5TN>PU";'_H5?EM^S_\ \ER\ _\
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M8^\>I7G^&OF/X/\ Q8UWX*?$#2_%WAZ8+>V;8>%B?+NH3C?$_JK#\C@]17[
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M'L'@S_H2M;_[_P 5?*?_  P[XQ_Z#>A_]]S?_&Z/^&'?&/\ T&]#_P"^YO\
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IC\"S+,*N:8NIBZ_Q2?W=E\@HHHK8\P**** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img60210087_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img60210087_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &Z <P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *P/%BJUGIZM#YRG4(08L [QD_+SQSTYXK
M?JCJ>G?VBMJ/-\OR+F.X^[G=M.<=>,^M %**TM(X+F2/0EL'6%L2&.$$\= 4
M8FN=M!;G3_"@NX//@Q/NC\DRY^4X^4 D\X[5W4T?G021YQO4KGTR*Q[/P_\
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M-I/_ ,)2M[L_T<61BWY'WMX.,=>E:E%% !1110 4444 %%%% !1110 4444
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M:[K&C.[!44$LS'  ]30 ZBFHZR(KHP9& *LIR"/44Z@ HHHH **** "BBB@
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M<>.?4%N2\[+?_9K:*-5#'@' Z#U.2:V+.\-VLFZUN+=XVVE)D S[@@D$?0T
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M[66:VATYH[^69P&6&3(B3N[$ X XX.,DUS,#I#%:32NJ11ZW*7=CA5'/4]J
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M_$C7EMIYM[+-U>F0K"\N BH2"6;!]/2M#3M1^VO<P2P^3=6S[)8]VX<C*D'
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M#4D4EXL%II<ZW$AD2>YCW20ECR,;2& ZCD>])+(FA:E/Y%Y8J\EM&LB7C&
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MHH **** "BBB@ JMJ)@&FW7VIF6W,3"1E!)"XY/ /:K-(RJZE6 92,$$9!%
M'*3-J.D:*DDK66JZ/%$I(DC*2E.-N.JG P><$X]:5I[G4M7U1#'J3) 1%"MK
M.L0CRN=Q!=223R,@BME= TU2H$#&-7+K"9G,2G.>(R=HZ^G%/NM&L;R=YIHG
M$CIY;M'*\>]?1MI&X?6@#$T^ZO-7O;&TO;AE461N)/LLVWS7WE,[XSTQS@'&
M3[56CO;T7MI;&YF:*#56M@Y?F1 N0&_O8]373SZ597"P!X=A@&(FA8QL@QC
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M&(C)SW'' YH ZJBLG3[L3Z[JL2PPJ(A 1(B8>3<I/S'OCM6M0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 51U/3O[16U'F^7Y%S'<?=SNVG..O&?6KU% %'4]._M$6@\WR_L
M]U'<?=SNVGIUXSZUFR^';AK6_LXM1$=K>2O*P,&Z12W4;MV",^V<<9[UT%%
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M.R=@%N61=F#T8C=N /')7N*U$D9I9$,3JJXPY(P^?3!SQ[@4 /HHHH ****
M"BBB@ HHHH *KFQMS?"\96:=5*J6=B%SUVJ3@'CJ!FK%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %87BE2]OIJJ[(3J, #KC*\]1D$?F*W:9+#%-L\V))-C!UWJ#M8="/0CUH Y
MO7K2:!M)>34+FX7^TH!LE6,#KU^5 ?UJF(K6XTO7KV_V#4()I=LK-AX-O^K"
M'JO.,8Z^]=?+!%/L\V))-C!UWJ#M8="/0^]12:?937*W,MG;O.N"LK1 L,=,
M'&: ,#2))4\1W$MZ1'*^G022;QMY ^8^V#GZ50TJQ^W:7I#QM8W+(DA-E>'Y
M64R'YU SR.F2I'-=?<6-G=NCW-K!,R?<,D88K],]*;)IFGRPI#)8VSQ1Y*(T
M2E5SUP,<4 <C&MC?3Z$%T](ECNYH'B=A*!M4G 8]5SR.U/$=M/HNN7][M&I0
MSRXE)^>%E/[L*>H&<8QUS76OI]E););/:6[01G*1&,%5/L,8'6DDT^RENEN9
M+.W>X7!65H@7&.G.,T <WIFGPZIKFI'5+=9I1;6VY)%X#,AW''8\=>HK6\+2
MR3>&+!Y'9W,>"S')X)%:BPQ)+)*D2+))C>X4 MCID]\40PQ6\2Q0QI'&O"HB
M@ ?0"@!]%%% !1110 4444 %5M0>./3KEYHGFB$3;XTZLN.0.1VJS10!R$C7
M&C:)%J6EZNT]BJ+Y=I=*K[\G&T.,$8' '/(JGKGS3>(.JYGLNAP1P/2NQ73-
M/2Z^TI8VRW&XMYHB4/D]3G&<T^2RM)3(9+6%S(5,A:,'>5Z$^N.U '*ZK$=)
MU"\328A;DZ4[E81MRRN &P.K %N>M-EL],MM1\-/8I&KRODE#S(NS[S>IR>I
M]3763VRR[Y(R(KDH46=44NHZ]QTSVK*M?#J17MO<S&TW0$LHM;00[VQC<_S'
M.,G'3K0!R]X0V@_VM"EM%NGS'<2N9+N1_,QC< H7Y0>.>!^-:4=GIEQ>^));
MX1L\4A(+GF)=@^9?0Y'4>@KIFTC37DDD;3[1GDSO8PJ2V>3DXYJK!H%HE]=W
M5S%!<M/-YJ>9""8N , G/I[4 8>E!]3U*PAUI%E']G+)%'.,AWS@L0>K8Q55
M46ZFTNWD_?62ZI/%;AOF5H0.!D_>7.1WX&*[6YLK6]55NK:&=5.0)8PP!_&E
M^R6Q$(^SQ?N/]5\@_=\8^7TX]* .2%HDVMZI;RZ?8RPVR(D,=S.8Q#%MY9 $
M;&3U88(-=#X?DEET&T>>X%PY3_6C=\XR<'Y@">,<D<U9N=/LKUE:ZL[><J,*
M98E;'TR*LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%8GB7_5Z5_V$K?_ -"H VZ*I:MJ
M TK2Y[TQF3RP,(#C<20 ,]N2*H/J6H:?>VMO?FUE%TC;'@1DV.JY(().0?7C
MZ4 ;E%<Q9ZYJ<FGZ9J%PMH8;R=(3%&C!EW$J&W%B.O.,=.]1ZG?7^J:!J\]N
M+=;.,2Q!&5B[JO#-NR .Y P>E '5T5S]G?7]VQLM/-M%]DMXM[SHS[W9 0
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M!;VEXS,R&'<R%OO;3N'!]"#WQBMZB@#'&C7%M.T]A?+#)+"D4WF0^8K%1A6
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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..BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img60210087_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img60210087_3.jpg
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# __
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M-2T"#L(*TS!Y#$G6;YB\L6DO8F;?DGG%-NG,3Z)$PR9:Q B8R#PO241DMR@
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MA/C?@;C?&6"&P/B>DXGBK7+DGK''4B%;0C28F$FQ6:<@]0; 4BCA-J0"%'8
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M+K^8Z7QGD!5W/5\Y"&'J!M$S99!F&W@4A4P^YI@=*KQY_8U4#A^&IU?DJF?
MJ8YI14#V^]-_X4U3:S92(E;KPSB0)#KF0E.WA*FBVHGA4%0S3J480Z#1!!H@
M@T00D7ZL3(17>5N)^+47*APA:+=[N\:@/[2DO.3;*&:*"&__ &QT(<__ *NV
MH#UDJ9U5'2 ^*VI1[I ^Y%M_HU[(6[#F+,"D@==5L,)/"0VVI9[DW!W84;%!
M<J)'!D5@;J',DFX%,X('5( "=,BVWEF4(!@$2@.X .H4D9;W!%GP<;+A:!'6
M 3(GC*&S_2I\DOR;S'G_ (KS$B!([)=7C<L4QBJ(B VFE*!#VA!KN/20[ZNR
M2*YP#Q,#+?W>$UZ/W;<J'[.X<%IWT\Z=O@/@BL#TCNGQJ+/:=1J1$U4[QIWR
M.!#PFF?('$8<1</'#Q.I\BI&#1!$Z?U(_)$N;>X9)XXB7_Q=8XVTF(QLW334
M*9N6WS&UINJO201 '#=S(-V9Q'Y6[7;PVVTLNJMV%=F$T39FU3("?QO&5X3+
MN1>3V!-/E95T=3F:J;W;A>ZA;X)&/4@]4UMX"E!4)827.- CED\9@W%XT=-
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MS9LVV.^K+-"[_6!ZQ0*5'F!V]R.74OL]:IZ44R;AFNW_ /*%$#SAA:7F4D[
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M_G(S!>[,T5ZNHOS.M.NT(1-,1$?VI*(;HE+[MM)EF&N-SO=15SF%NJ([I/\
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M$8<"1&T3651 4&B",3LF\$^'.9[M*9'ROQLQ'D&]S;=BUEK7::A&RTU(-XQ
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M_=Q[V*B'9I^R[X5_4U'?CF9TW63OJQ1^1^Z8UV.TE]N>9?I _%MQUEWDNYQ
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M-G;M)(QDB',45 */3OL.T.AIPMET)/5@R)EAWXLC5<*)%8FWK=;%:M)4E!4
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M,R.4A/\ 5J:2$C@G(%1YRH^ 1>]V%=/+?D_1:DS"EL?+5[*JEUPCI;A4I#*
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MUS->*B_WQY51=ZIPK=<( *UG:2$@ ;-@ '$(YWKL1Y$>!$"@(B(  !N(B.P
M >T1$?  #1'Z 29#;'@IBG#J*8I@'WE$!#_I#<-$!!!D<#'MHC\CU,<A-NLY
M2;^ =1@+N/W W$-]$P-L?H2I7B@F/;1'Y!H@CT%5,!$!4( @.P@)R[@/W!#?
MP'7Y,1];BN(QY*8IPW*8I@ =A$H@(;_<W#WZ_8_""-N$>VB/R(T)OP3?J#_0
MTC VQM7+\0\QBI5V:OLO^&'U0MOQ_.Z;W(_U3H?(_G&-<_M2_P"8+-/TE_[3
M<;--95$ P:((-$$&B"#1!'Q;)8(FI5V>M4\[(P@ZU#2<_,O5! $V<5#LEY"0
M='$1 .E!HW.8?$/ -<;KJ&6E/.&3:$DD\0 F8[=!0U-SKF;=1I*ZRH=0VA(]
M<M:@E([I($24N8_(64Y6<I<[\AIA4YOSGY%L$]%$4$_]A51LX-&U-@0AQ$4D
MV-;8MB='@ " ^'CI-<PW)R[WE^O7B7'"1S$R2.X)"-EC1W)5'IUII:<ITX"6
MZ*B0E9XUI3O.K)&W><+BQR&&]>-W;(=V_P!.Y=<8NH40RWF>O3/+"O-ED#)O
MDK;$"WL&.V'E=(J"[D:;7T6A0\!W?B'A[-3?:<JE6G"Z10_K;R2^.<8I'=0)
M=V*M-0]?$L]M&GS PY*P6UY%I49X=6LE+ZY\ 34.%?,WPPCZR>R,<[9R4<NY
MC)F-=M9!@Y2,9!Y&S,8Y(Y:K)F\#HN6;]N @/M*8NE\2I=)4!0)"FU;>3C[V
M,7"OM4^8+,IE:4K9JV/%.()(Q2>0JP/(8J^=NCD['\PN%O'_ #XU<$5E+;0X
MMG<$2J H=A>JX3Y@N+)80]BJ<]'K&\=ODG ??IQ\N7--WLM/7 S6IL!7MA@K
MPB-;/6C(SNG6IMWRHI)33L52E,S$IL.'K&C+VB@.<&,V->W$70:((-$$&B")
M?7>[^U*Y=_P^C_HO!Z4K4'ZVUGE/S1&PQV/_ /+QEO\ <S\:Y#-?I3?T1^0O
MU](_0R(U+.C_ ,R5'EQ[T17SZ1S[4+/]$J^/7#36I<BNV#1!!H@A>?U.?V8;
M_P"OW#_]4L6HYU2^JJO+H]14.?V#?M\:^BJGW[$([\ 0$><W$(  1$>1N*=@
M !$1'\JF/@ !N(CI?<I_6&D\LCWR8N"[0/V.Y@^CJGXAV*T&G(C6N@T00:((
MGG^I\W_XD<-X"&_'B@B&X" "'SS90W ?>&^EMU;^L"?)(_.B[+T>'V0O?2%3
MZK493^DR_P!?',KZI\5_2JPZ]?1K]9K/)I]^8COTE?S)EW]]>_L[</$ZGN*D
M8-$$&B"%^_4B<HOS#]OB9QA"R1V5UY/6>/Q7'$0$0<%IK7HL&0G?40P*)(FA
MV:;(QO8/QP%$?'88]U+NXMF7%LI,GJA6X/:C%7?P'=AQ>Q#IVYGC6ABY.H"K
M=9VC4*)X'5?!LRXRDE3@XMR?!"/W;EXVON67-SCE@UHS.YAY_(L+-7'9+SD6
MM"IBQ;-:E71?  ;K1,6=#Q]IUBA[]+[E*V*N]_IZ0B84X"KVHZ2I]P'OQ;_V
MAL],:<Z1WC,*5!MQJD4AD3D2XH=4P$\O6*09<23&^GU4'%P*9FG G*BNQI&]
M?R33E<06Y1N4>A&TT !?595?I+LF#VJOA;I=0B(@P$ ]FI&U>M'55+%U;'P;
MB-P^V1L[Z3^3"8>CHU#\^LEVR#6N3JZ6H\Y;!X6JCQY<>Z^DD^5''&OGT_')
MX..7<7QU#2TE\!3,_P :^PQ9 56(@S"4ES%D:.^=&4,4F[>S,TVY!]H?%B'O
MUB^F=X^3,R-L.&5/4@MGBF?%\('?B=NW!IP<]:)U=THV]^[V52:M$@2HMHF'
M0)?ZM2B>1 BE%IIHH4@T00:((-$$3HO4J9%3NG<QL%:;+^<UQEBG'=5V VY4
MG\@Q7LK]/I_8&*I,% ?N[;Z6/5:J#^9U-#Q6FD)[LMX^K%Y_8!L2K7H:S7+$
MG*ZOJ'OQ0L-)/=#<8_,^/#BR=CV0Y!M85%1_C[GF\8/)=)N07I*//8]B:XZ*
MX7*7S18(6Y9J  (])3J>SQUTC:R[I\+@$C?;K9$RQW5( [V]*,F3GM%%VP5Y
M/<?5YO699*DME71#[54I6 V;Q9"SR@<D8I]NSD6MQ2YK\=,XBX4;Q-4R/#,[
M6":IT2KTZRJC7+0@N8HAU(?-$DH<0'<-R /NUX&5;F;/?Z:OGT$N#>Y4G!7@
M)B6M?,C-ZC:27O*A2#4OT2RR9 E+[8ZQHB>P]8A([L5@F;MK(-&K]DNDZ9/6
MZ#MHZ0."B+EJY2*LW714+N4Z2R1P,40\! =]..E04D*29I(F(UM'6G&'5,O)
M*74**5 [009$'E!P,=;YLRG7L'8?R=F*UN$FM=QE1;/=Y958X)D,VKL0ZD_A
MP,82AYCM1N5(@;AN<X!KJU]6W043M:[^C:;4H]P3\.R/<RGEZLS;F:@RS0 F
MLKZMIA,N N+"2>9()4>01(QRGD.R9HR?D+*4\9U(6K*-WL=O>%,)EW2\M;II
MR^1:)[;F4."SXJ290]P  :3*K>=N-S6\N9===)/.228V8,O6R@R9D>FME,$M
MT%OMZ&T< "6VTMH/).0//.-M'>IXY?Q9KMPDH(L2,W;;@AAAC/F*D5(SJW0:
MLTPL[A0I2E_;#/QV-ON.X;;ZS'4"V?);]"Q*1\Q:!]L-X*\,+;V0L\_QW:\U
M73>*D'-=<I'#)E?5*: /M9QGUZ5'(:4+RJY!8W75,'Y<8:833%'S *0[RI6=
MJ98P)B/RSE92I_$/8&LAT=J0W=JFE/\ I&01SI4/N&(?])#9%5>G]EOB!^J7
M-2%&7K7FE 8^V0(>\TPT4XP:((XS=)A[7J=;)^,:@^D8.LSTQ'LA(=0'CV,B
MW3UJU%-+]L.#A= I-B_*'?8/'7%4+4TPMQ FM*"0.,@$B/0M-*S776EHJA6Y
M3O5#:%*V;J5K"5''# $G&$F.P1QDP9W >0'-+DQS&B8C.F78:ZQCIE3\@*FE
MFB"]U<SCZ6N<C .EMY,C8S!.+8$7(=HP22%,A -T=,&Z?6N@S'75ETO8%16!
M0(2O$ J)FK=Y) ">SO1:?VP,^9MT6RMEW(FE[CEGRXME25/4X"%J2PAL-MAT
M##>"BXHI(*SC/QI\O]0CP_P!P1D.*/+[B)7XSC[F)++"L:6'QX<\#&S"]98I
MV6/M,?$-E2D82$6NF#)[\.!&[MH\(FJF/M-V-0K+;LO+I+S94"GJ^MD0C '=
MQ!EQ@X8<8CRNQ[J9G'6*FS!IMJ94*O.710AQ+E2 XXWUI+:VRX1,H4F:P%3(
M*5$'9)Q[$UGD[MBW&]RFF@,)BV4.HV258@'2#.2FX!A)/6P%_8@BY<F* >[;
M4S4;JWZ1I]P26MM*B.4@$Q6?F2@I[5F&NME(K?I:>L>:0KC2AQ24GN@".P-=
MF/%@T00EEZL+!8M[%Q5Y)1[("IR$?;L.69XB@'REV:J-LK!GBQ0WZA2=/R)=
M0^(%$ ]FH,UBM_ZK<DC:%()Y1TA/N%46J^C=S?A?<E/+Q0MJJ;23ZUP%IS='
MMDMDRXXTY]A[.08+[G?'QX[<@VA,HJ6+"TZ=1;R4 2O,:880RP"/2H);/&LR
MD ?V1O#QU@^F]Q\PS2RE1DV]-!_&$O5W8:?MK9-.;=![FZTDJJ[<$U20!,_
MJ"CRCX,NQ39TU<4!PD;ZKC//SODWC+QLCGH';4ZMV3+UH9D5W DO9%RUFK>>
MB41V43CF#XY1-X]*OA[=0-K%<@7::UI.Q)61[; > 'OQ;-Z-W):FZ&]Y[?1(
M..HIVU$;0T-Y8!\HM!/M>2,-.R=Q9LV=^+_=MEXMH95&<XH.L.P @43G=6Q^
M$AD%JV0( "*ADU:BVZ@#QW4* >(Z\;3^UO5EGNRT#!5(4#VQZ8]X(DKM?9[M
MV6M2-/J:I4 IJ_IJ%SV!E #"B>($U"N\87?:NGK0&C]BJJSDV!VSYFN0137:
MR,<J1P@J0? Q%D'* "'O 0U&*%&GJ@H&6ZO;R&'IJ&4W>P*96D*ZVFV'85)&
M(/.001%:;@;GUARAX<\<L[,5P75R!BJJR$S^V%440LS&/3B+2U7$/P5F]@CW
M)3 /B&WZ^G)L->+G9J:M'C+:3/VP$E>$&-:K5K*:\D:DWG+*OT5-7N]692!:
M6KK&B.3JU)CK?NFYO3X\]OSE/DLKY)C*-L53]9KIU!#J6L5W3+4(E% H_AK
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M^F9)X#HTN_7>F(2ULLB4JA4K5-5U"2*2PTPJ1GZ44[;$>'0*H8""J!@*!S
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M4H5W8I0]P:RXZAYL)GYVY^3_ "87=/8W[/J4A/\ #M(9<?7?[Z/3_C=]U/\
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MF31!D?&MA6,9R6,0$)*+9BB](1(  R<16^R9RM#/\84FZ''%%:FP-J%=(DH
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M,9W^BY(@SF3F,?W*KW:+,0PE,#ZL33*::[" AL!E&8 /WATKE"^NDK&JEO\
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M3F?_ '=B;^]+3K,]&OT%9SH_.A9_25?.N7/)U/J,PY/J;HJX@T00:((XE?\
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M-<\TI31<JJF++B8]PQLX(7P,@E79=1488ARB(;L%&I@$PF =_'7N63.5^L1
MHWU%B?B*Z23^*<!W)1%NI_9LTFU60M>9+6RFZ%,A4-#JGT_[5$E*EQ.!P2 $
MI80V_P  O4NX(SO,5[%_+VKL^.&0YIRVB8O(;*06E,*STHX-Y+9&2DWA0E:
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M2<$J 2)@DX@&>$L!P\<A$/=FGLPYXROJ+3:@ZCABT9>LF^_-;S2ENN!"DI2
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M0W_T1FKXP&#V"&H)RI5>9Y@I*B<@EY'>F ? 8M?[0%A_B/1_,%H"2M;MLJ
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M,D5#KC!,Y?I&E[OY83$RZ"F5X";@K$T.*;F"F8><;*%\#$6BW[9^D<OWRG0
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MSJ,K>\DL(X.E9T_59*+M;'5V3$4?F^;6%!Z] XD63,=(Q]9GDQ6:$4SE'F)
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M<PV2MRU?:S+]R245]%4N,. X$*;64'OD3')'.M=B/'@T01-R]1G]J?ECZO\
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M]0B3X8C@@ 7Y1BB(%U.6DK##%%5)8>0\GK$XI"QP'V:$>"<56>D*NETNF9[
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3#1!!H@@T00:((-$$&B"#1!'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>tern-20221220.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-12-23T11:41:23.0923+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.ternspharma.com/20221220" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:tern="http://www.ternspharma.com/20221220" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tern-20221220_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tern-20221220_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>tern-20221220_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-12-23T11:41:23.7198+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="tern-20221220.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10200.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName" order="10150.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>tern-20221220_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-12-23T11:41:23.1579+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information, Former Legal or Registered Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140060969455712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 20, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 20,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Terns Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001831363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-39926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1448275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1065 East Hillsdale Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Foster City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">525-5535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TERN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>tern-20221220_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tern-20221220.xsd" xlink:type="simple"/>
    <context id="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831363</identifier>
        </entity>
        <period>
            <startDate>2022-12-20</startDate>
            <endDate>2022-12-20</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_70cae8a6-f93f-4355-b4c0-48ecb92d83ab">0001831363</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_670ea391-7606-4662-8217-3bde398a9fee">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_6dde87ab-255e-49f4-a80f-a2a0e639d420">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_6fa2c7cb-9ebf-4771-a53f-e99bab4ade82">2022-12-20</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_e7e7d471-8020-4f02-9ca4-9983769a12d5">Terns Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_36c2503b-6de9-42ce-a505-59185812da68">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_3e0b09e9-4aec-44d9-89db-4d2bdc55d4c1">001-39926</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_fba26801-fae5-406a-abf8-356380d050e4">98-1448275</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_7d1433b9-525a-4ed6-8625-a830bfe198a4">1065 East Hillsdale Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_d30cac4a-3edf-4fe6-94ca-f69d63c8b112">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_5a889093-8885-4358-9316-750fba17331b">Foster City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_15e1a5c9-ccf3-4854-ada7-e6cc8945844b">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_54c451eb-dc4d-4427-b454-bd55e46078b5">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_0eaa1010-eef7-4889-bccc-79408da2a5e3">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_724c6679-48ce-46fb-9cac-c2b0c03a3a3b">525-5535</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_144144a4-72f6-4308-85e8-0ec04476a354">N/A</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:WrittenCommunications
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_2c7b914d-1c50-4a97-a461-41a5f86ea43b">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_43ac8139-8d66-492d-a3ba-57827a5f834b">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_adfd61fb-03a4-4cb9-bd78-b8dd80239d5b">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_c18f266f-3d5b-4193-8d22-f9c1bb103f80">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_4d0721e5-7d65-4091-b6e2-feab82498be7">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_2d63acae-de75-4d38-819f-52db76da48e0">TERN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_6f0de68c-9370-4269-9bf6-e81e90068a89">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_7b20e325-8dd6-4c63-b919-bd9028b94189">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_8119cdd3-b633-4fc9-a3f7-353dccdb674d"
      id="F_cffc3da8-85fa-4c3f-acb1-1494f1520d29">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M;D!^Q9\2MN;HF+FI+)1Z=2>/X;#A.2*((+!.0N#'!B8014X).;[N11O%/=W
MX^.#^D,^>9S,0AB8J.B+#.UZV.@U6 A+D47V16T_P'Y"':<7J,CD_]EV=VV'
M-UB0&:OB_6 DB&6R^Q1O^T <#6B?&L#W WC.O;M13GDGK!@-M-HR[:Y&-7>0
M3S4?C7 R<:LRLQI_E3C.CNY4D&&0+1LG(;M/K+3O[#'9K39&;="T>!-W:3/8
M"][N!/DI00BN&/<N\(_S_PYO(EL!R M GNNU3NA-U 8T^WN\,%;C$OY31;13
M:%<KN+R^,:D(8-C Q#6@-] 8_?2#W_5^)?A:!5^+4B\#.']/H0J.'MZ[_$A
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 3H&753JJHN=  0  / (   \
M  !X;"]W;W)K8F]O:RYX;6R-45UKPS ,_"O&/V!)RU98:09CW4=A;&4=?7=B
MI1&UK6"K[=9?/R4AK+"7/<DZB=/=>7&BN"^)]NK+NY *W3"W\RQ+50/>I"MJ
M(<BDIN@-2QMW66HC&)L: /8NF^;Y+/,&@[Y;C%SKF%TVQ% Q4A"P [8(I_0[
M[UIUQ(0E.N3O0O=O!UIY#.CQ#+;0N5:IH=,+13Q38.,V523G"CT9!EN(C-4?
M>-.)_#1EZA$VY8<1(86>Y4)88TS<;_3\1C0>09:'[L#TA(XA+@W#<Z1#BV'7
MT8B+[,)&G\-8AQ#G\3\Q4EUC!4NJ#AX"#SE&<)W D!ILDU;!>"CTN*+N@U6/
M@24DM0H#E>QV3N7TR@ZN6>1>9!CG*(.XLH/P4:V%&@/8-SF0!)?DJG547>EY
MIM<WDUM)Z.#<@V#OX96,'<V/'W?W U!+ P04    " !.@9=5)!Z;HJT   #X
M 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( $Z!EU4)KNY9[0   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $Z!
MEU697)PC$ 8  )PG   3              "  <L!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ 3H&7574WP0>]!   E1(  !@
M ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $Z!
MEU6?H!OPL0(  .(,   -              "  ?\,  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ 3H&759>*NQS     $P(   L              ( !VP\
M %]R96QS+RYR96QS4$L! A0#%     @ 3H&753JJHN=  0  / (   \
M         ( !Q!   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $Z!EU4D
M'INBK0   /@!   :              "  3$2  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( $Z!EU5ED'F2&0$  ,\#   3
M      "  183  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(
' & 4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>25</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tern-20221220.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tern-20221220.htm">tern-20221220.htm</File>
    <File>tern-20221220.xsd</File>
    <File>tern-20221220_lab.xml</File>
    <File>tern-20221220_pre.xml</File>
    <File>tern-ex1_1.htm</File>
    <File>tern-ex5_1.htm</File>
    <File>tern-ex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tern-20221220.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 25
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tern-20221220.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tern-20221220_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tern-20221220_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "tern-20221220.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 26,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 25,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "tern",
   "nsuri": "http://www.ternspharma.com/20221220",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tern-20221220.htm",
      "contextRef": "C_8119cdd3-b633-4fc9-a3f7-353dccdb674d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tern-20221220.htm",
      "contextRef": "C_8119cdd3-b633-4fc9-a3f7-353dccdb674d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Legal or Registered Name of an entity",
        "label": "Entity Information, Former Legal or Registered Name"
       }
      }
     },
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ternspharma.com/20221220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0000950170-22-027006-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-027006-xbrl.zip
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M_6;F1C_[6L=%"4"/EK"V\&[(#7.)WGCF9LV1FB,U1UZ2(T93?Q9'BO*[MND
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M9!AP>]]_@B>TA*X3X#=TBWW'H_Z"(3@=/)[!MS]>'^ !DQ\CVT=P2YW%#)$
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MEU5RALK)<*P  +>B!@ .    =&5R;BUE>#%?,2YH=&WLO>MVV\B2)OK[G*?
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M2545=B7-9;HTJHM<5/K]E08Z&@][AJM(GV)Q6L;-'#%C"+]@0B"#G05+&(N
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M45G.C"L^:SM7%158(W^L9LWINFU/58[573,L>ABK!?9Z"&H_0E#[Q1#4WH=
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M>13]S%=1J:1ZRV;!_FS=JLZCLMW@5#_& ^KZX16'Z(4&C@L0%94NB8:YC!3
MWT; AMZ^*%%_-@)A$%[.'9C5V$.ZF3?R2TH]H8NT33$Y*8MYP- 5'#<9S'
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M)EQG^<XK&;;^9;B!B=GN];TJ]-N&P/@1GOS3(SWYWT2,IC18FK/@:Y\4CZ5
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MGZAL#KOW--P+&/OJ".BOY_8Y/.0S+!ZOY#-ZG6G)L84$1@^2I39CS#"H.3-
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M*#]?WF-VE\H OW&E&/_!ZX2E#=<FG\Q\'8\1<B%9,?,$/))6KL[%;PSXV\?
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M]ZAZ!U_OH?MZC[6X9H^O]^"X#-^TG+;BZPVU\R^SM6;(+XA0_2U^8(\<"UW
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MTFF5VK;G:<?8N.E1SI8$C966:T^W9/&3]DJ15=QX9AAA1Y*84HV(]*-:M)2
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M2R##O16UEA@M,5IB;*-%?@=:&O9FRO&4!"HK$IZ;B+V62??^VN8'2.=^[_"
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M;4DT$21HHOAAY-UW!5)ZQ;FX+D0./;""+W@$]44+#SR  TO0X]B2/!569;P
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MZP<;G&F_P%R5:4)+EGG*YY.2PF2I=!V#K 5:&'Y74O&1?$&UO2WN7!ECLW@
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M\\,G[O?J_P-02P$"% ,4    " !.@9=5LZ9T[<,7   0! $ $0
M    @ $     =&5R;BTR,#(R,3(R,"YH=&U02P$"% ,4    " !.@9=53U^3
M:PP#  "M"0  $0              @ 'R%P  =&5R;BTR,#(R,3(R,"YX<V10
M2P$"% ,4    " !.@9=58;V-\!,&  #K.   %0              @ $M&P
M=&5R;BTR,#(R,3(R,%]L86(N>&UL4$L! A0#%     @ 3H&759:V+0/-!
MNBD  !4              ( !<R$  '1E<FXM,C R,C$R,C!?<')E+GAM;%!+
M 0(4 Q0    ( $Z!EU5RALK)<*P  +>B!@ .              "  7,F  !T
M97)N+65X,5\Q+FAT;5!+ 0(4 Q0    ( $Z!EU4ZH,3S( P   -<   .
M          "  0_3  !T97)N+65X-5\Q+FAT;5!+ 0(4 Q0    ( $Z!EU6(
M" 8UDPP  +8^   /              "  5O?  !T97)N+65X.3E?,2YH=&U0
52P4&      < !P"Y 0  &^P

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
